



Neuroglobin Expression in the Brain: a Story of Tissue Homeostasis Preservation

Zoë P. Van Acker¹ · Evi Luyckx¹ · Sylvia Dewilde¹ 

Received: 22 November 2017 / Accepted: 26 June 2018 / Published online: 10 July 2018
© Springer Science+Business Media, LLC, part of Springer Nature 2018

Abstract

After its discovery in 2000, the notion grew that neuroglobin, a neuronal specific heme protein, is involved in cytoprotection. To date, neuroglobin levels have been positively correlated with a beneficial outcome in a plethora of neurotoxic insults, e.g., ischemic and traumatic brain injuries and Alzheimer's disease. The first part of this review goes further into these changes of neuroglobin expression upon different neuronal insults as well as the underlying regulation. In the second part, we shed light on the mechanisms by which neuroglobin contributes to neuroprotection, being (i) the scavenging and detoxification of reactive oxygen/nitrogen species, (ii) the augmentation of the threshold for apoptosis initiation, (iii) its contribution to an anti-inflammatory milieu, and (iv) tissue regeneration. We also consider different neuroglobin models to address as yet unanswered questions. Based on the recent findings and progress in the field, we invigorate the avenues of neuroglobin in neurological ailments to increase in the coming years.

Keywords Neuroglobin · Expression · Neuroprotection · Apoptosis · Inflammation · Neurogenesis

Introduction

Sustainment of homeostasis in the central nervous system is essential to support vital physiological functions. In multicellular organisms, the maintenance of tissue homeostasis is based on a balance between cell death on the one hand and cell survival and proliferation on the other [1]. In case of a toxic insult or pathology, tissue integrity is preserved through an interacting network of signaling pathways, often including the activation of hypoxia-inducible factor 1 (HIF1) [2]. HIF1 modulates processes as erythropoiesis, angiogenesis, glucose transport, and glycolysis, allowing adaptations to oxygen delivery and metabolism [2]. Interestingly, globins are a class of hypoxia-activated, gaseous ligand-binding, heme proteins of which the ascribed functions surpass transport and supply of oxygen, the function for which they are best known [3].

One of these globins is neuroglobin (Ngb). It shows a widespread expression in the central and peripheral nervous

system [4, 5]. Highest expression levels are detected in the mammalian hypothalamus, which shows 100-fold higher transcription rates than other key *Ngb* expression regions as the cerebral cortex and hippocampus ([6] Fig. 1). Pronounced levels are also detected in endocrine active regions of, e.g., the pituitary and adrenal glands [5]. Like neurons, these cells sustain high metabolic rates. Being confined to high oxygen-consuming cell types, *Ngb* was first proposed to play a central role in the maintenance of cellular oxygen supply. This hypothesis, however, was hardly tenable in view of *Ngb*'s relatively low concentration (up to a μM range, or below 0.01% of the cerebral protein content [4]) and its oxygen affinity (P50) value of 7.5 Torr. The latter is below the oxygen tension existing inside neurons under physiological conditions [8]. Further elucidation of *Ngb*'s structure and subcellular distribution entailed the premise of a better understanding of the vital biological functions performed by *Ngb*, knowing it to exhibit a 3-fold slower evolutionary rate as in comparison to other globins as hemoglobin and myoglobin [9–11].

Though *Ngb* exhibits the classical three-over-three alpha-helical globin fold, generating a hydrophobic pocket for the central heme iron atom, its protein sequence only reveals an up to 25% identity with sequences of other globins as hemoglobin and myoglobin [12]. *Ngb*'s unique sequence supports the heme iron atom to be both hexa- and pentacoordinated, with the HisE7 residue and

✉ Sylvia Dewilde
sylvia.dewilde@uantwerpen.be

¹ Laboratory of Protein Science, Proteomics and Epigenetic Signaling, Department of Biomedical Sciences, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium




Fig. 1 Cerebral expression pattern of *Ngf*. Mean “reads per kilobase exon model per million mapped reads” (RPKM) values are indicated for the different areas. Values were obtained from a meta-analysis study

on transcriptome data (RNA-Seq) [7]. PTLP posterior parietal association areas, Sub. subiculum, CTXsp cortical subplate, VTA ventral tegmental area, SNr substantia nigra

the ϵ -amino group of LysE10 to function as endogenous ligands in the hexacoordinated state [10, 12]. Beside the sixth coordination position of *Ngf*'s iron atom being involved in the regulation of exogenous ligand binding [13], its valence state (ferrous or ferric) has been found implicated in *Ngf*'s ability to interact with nitric (di)oxide [7, 14, 15] and reactive oxygen species (ROS) [16]. Moreover, ferrous (Fe^{2+}) *Ngf* buffers limited stress signals and maintains homeostasis by swiftly reducing leaked ferric (Fe^{3+}) cytochrome c to its inactive form [17], averting cytochrome c-induced apoptosis. In view of the neuroprotective nature of the latter interactions and the cellular redox state playing part in *Ngf*'s ability to engage in cytoprotection, it is hypothesized that *Ngf*'s functions are modest within physiological conditions and only come strongly into effect under cellular stress. In support of this idea, *Ngf* is a particularly stable protein. It retains most of its structural features under acidosis, a common side effect of cerebral pathological conditions as hemorrhages and pneumococcal meningitis [18]. *Ngf* expression is also upregulated in a plethora of neurotoxic insults; both studied in vitro (Table 1) as in vivo (Table 2). Given the wide variety of neurological injuries upon which *Ngf* expression is induced, this suggests the involvement of generalized or downstream pathways of tissue integrity preservation to which *Ngf* expression responds.

Ngf Expression Regulation

Hypoxia-Linked Elements—HIF1, SP1, mTOR

Despite the unlikelihood of *Ngf* having a primary role in maintaining oxygen homeostasis, its link with oxygen is strongly present. Many of the neurotoxic insults that increase *Ngf* expression are characterized by a direct (e.g., hypoxia) or indirect (e.g., ROS) dysregulated oxygen metabolism. Hence, it may be of no surprise that HIF1 levels are positively correlated with *Ngf* levels [11, 53, 75]. Though it is already noted that this is not a universal finding in all studies investigating *Ngf* expression under hypoxia (vide infra [50, 65]). The latter may be grounded in the regulatory elements upstream of *Ngf*'s promotor lacking a binding site for HIF1 [9]. As two GC boxes in the region around the transcription start site are bound by transcription factors specificity protein (Sp) 1 and Sp3 [9, 76], it is hypothesized that HIF1 works through Sp1 to upregulate *Ngf* expression. Such a HIF1-SP1-*Ngf* axis is proposed, knowing Sp1 to participate in sequential gene activation downstream of HIF1 upon cerebral ischemia ([77] Fig. 2).

Increases in *Ngf* levels originating from other cytological events could be promoted by HIF1 activity as well. The thyroid hormone 3,5,3'-triiodo-L-thyronine is involved in neuronal migration and differentiation and regulates transcriptional responses related to mitochondria, neurotrophic factors, and the myelination of axons.

Table 1 In vitro alterations and neuroprotective actions of NgB

Neurotoxic insult	Model	NgB mRNA	NgB protein	Neuroprotection	
AD					
Extracellular Aβ(25–35) 20 μM	Primary cortical cultures of NgB-overexpression mice	n.d.	n.d.	◦ Cell death about halved after 24 h	[19]
Extracellular Aβ(1–42) 100 μM	PCI12 cells, NgB-transfected (~4-, 8-, and 16-fold ↑ NgB mRNA)	n.d.	n.d.	◦ ROS/RNS ↓ is NgB dose-dependent	[20]
APP Swedish double mutation: K670N/M671L	SHSY5Y cells, NgB-transfected	n.d.	n.d.	◦ Lipid peroxidation, caspase-3/7 activity and cell death ↓	[21]
NMDA toxicity 300 μM and 2 mM	Primary cortical cultures of NgB-overexpression mice	n.d.	n.d.	◦ ↓ Aβ ₄₂ : 34.1 to 21.3 pg/ml medium	[19]
Tau pathology	HEK 293/tau cells, EGFP-NgB-transfected	n.d.	n.d.	◦ Late apoptosis: 4.43 to 2.53%	[22]
				◦ At 300 μM: ↓ cell death	
				◦ At 2 mM: NgB overexpression no effect	
				Counters tau-P at pS214, pT231, pS396, and pS404	
Anoxia					
8, 10, 12, 16, 24, or 32 h of 95% N ₂ , 5% CO ₂	SH-SY5Y cells	No significant increase	n.d.	n.d.	[23]
48 h of 95% N ₂ , 5% CO ₂	Glioblastoma: M059J, M010b, M059K, M006x, M006xLo, U87T, and U87R	Between 2- and 10-fold ↑	Intensities ↑ up to 5.4-fold	n.d.	[24]
10 h of 90% N ₂ , 5% CO ₂ , 5% H ₂	Primary cortical cultures of NgB-overexpression mice (2.6-fold ↑)	n.d.	n.d.	◦ 14 h: ↓ lactate dehydrogenase, not at 6 h	[25]
99.99% positive pressure flow-through of N ₂	Primary neurons of <i>Tracheomyia scripta elegans</i> , siNgB-transfected	n.d.	72 ± 6% ↓	◦ Amelioration in oxi-HE formation, ATP level decline, and loss of mitochondrial ΔΨ	[26]
Axon disruption					
Axonal damage seeing culturing	Primary retinal ganglion cells of male Long Evans rats, NgB-siRNA-transfected	n.d.	n.d.	◦ Knockdown no effect on cell death	[27]
				◦ ↑ Levels of activated ERK (p-ERK)	
				Cell survival at day seven decreased to 16.0% (control 46.6%)	
Hypoxia-reoxygenation injury					
◦ 1 h Argon-degassing	ND15 cells	◦ 2 h: marginal ↑	n.d.	n.d.	[28]
◦ 2, 5, or 24 h recovery		◦ 5 h: 5–6-fold ↑			
		◦ 24 h: baseline			
◦ 1 h Argon-degassing	SH-SY5Y	◦ 2 h: 1.9-fold ↑	n.d.	Pre-incubation with the phenolic antioxidant 3,3',5,5'-tetra- <i>t</i> -butyl-biphenyl-4,4'-diol reduces NgB expression	[29]
◦ 2, 5, or 24 h recovery		◦ 5 h: 7.0-fold ↑		◦ Unchanged average cell area (Wt: 1.6-fold ↓)	
		◦ 24 h: 5.9-fold ↑	~ 95% stably transfected	◦ Intracellular ATP preserved in transfected cells	[30]
		n.d.		◦ Less evident actin condensation	
Infection					
500 ng/ml LPS for 5 h	Primary mouse cortical astrocytes	n.d.	~ 2.3-fold ↑	n.d.	[31]
500 ng/ml LPS for 5 h	Primary mouse cortical astrocytes, siNgB-transfected	n.d.	Reduced with ~ 70%	◦ ~ 2-fold higher IL-6 mRNA levels	[31]
500 ng/ml LPS for 5 h	Primary mouse cortical astrocytes, 10 pM E ₂	n.d.	4.5-fold ↑	◦ ~ 1.5-fold higher CXCL10 mRNA levels	[31]
				Prevents LPS-linked elevation of IL-6 and CXCL10 mRNA levels	
Parkinson's disease					
C-terminally modified αSyn aggregation	Human neuroglioma cells (H4), NgB-transfected	n.d.	n.d.	◦ ~ 2-fold lower number of aggregates per cell	[32]
				◦ No impact on lactate dehydrogenase release	
OGD					
◦ 8–32 h 95% N ₂ , 5% CO ₂	SH-SY5Y cells	◦ 24 h: ~ 2.5 × ↑	n.d.	n.d.	[23]
◦ No recovery		◦ 32 h: 4.2 × ↑			
◦ 16–24 h 95% N ₂ , 5% CO ₂		n.d.	NgB/actin ↑ from 100 to 25,000%	◦ More cell survival at both 16 and 24 h	[23]

Table 1 (continued)

Neurotoxic insult	Model	Ngb mRNA	Ngb protein	Neuroprotection
<ul style="list-style-type: none"> ◦ No recovery ◦ 4 h 90% N₂, 5% CO₂ ◦ 20 h recovery ◦ 4 h 90% N₂, 5% CO₂ ◦ 4 h recovery ◦ 4 h 90% N₂, 5% CO₂ ◦ 20 h recovery ◦ 4 h 90% N₂, 5% CO₂ ◦ 4 or 20 h recovery ◦ 4 h 90% N₂, 5% CO₂ ◦ 20 h recovery ◦ 4 h 90% N₂, 5% CO₂ ◦ 4 or 20 h recovery ◦ 36 h 95% N₂, 5% CO₂ ◦ 12 h recovery 	SH-SY5Y cells, NgB-EGFP-transfected Primary mouse cortical neurons Primary mouse cortical neurons Primary NgB-overexpressing transgenic cortical neurons (~2.7-fold ↑ NgB protein level) Primary mouse cortical neurons, AAV-NgB-transduced Neuronal mitochondria of mice, rNgB (90 μg/ml) co-incubated Primary mouse cortical neurons, NgB-shRNA-transfected SH-SY5Y cells, NgB-CPP-transduced (1 μM or 600 nM)	n.d. n.d. n.d. n.d. n.d. Transfection efficiency ~40% n.d.	1.8-fold ↑ 1.8-fold ↑ in mitochondria 2.5-fold ↑ 4.6-fold ↑ n.d. n.d. n.d.	<ul style="list-style-type: none"> ◦ H₂O₂ levels are about halved n.d. n.d. ◦ ~50% less neuronal death ◦ Counteracts downregulation of <i>Camk2g</i>, <i>Hif-1a</i>, <i>Il6st</i>, and <i>Klhl3p</i> ◦ 16.4% less neuronal death ◦ 0.26-fold less NAD⁺ level decline ◦ 0.82-fold less NAD⁺ release ◦ 0.47-fold less Cyt c release ◦ 23.5% more neuronal death ◦ 1.61-fold more Cyt c release No significant improvement of viability
Oxidative stress 24 h 300 μM H ₂ O ₂	SH-SY5Y cells, NgB-EGFP-transfected	n.d.	Optimal 12 h after transfection	23.6% cell survival (only 11% in control cells)

AAV adeno-associated virus, APP amyloid precursor protein, AD Alzheimer's disease, CPP cell-penetrating peptide, E₂ 17-oestradiol, EGFP enhanced green fluorescent protein, LPS lipopolysaccharide, NgB neuroglobin, NMDA N-methyl-D-aspartate, RNS reactive nitrogen species, ROS reactive oxygen species, OGD oxygen-glucose deprivation, Wt wild-type

In addition to its classical activation of thyroid hormone response elements, a nonclassical mechanism was detected in which PI3K is activated by liganded thyroid receptor-β [78]. PI3K, in turn, upsurges transcription of *HIF1* [78]. Hence, when intravenously administered to thyroidectomized rats, 3,5,3'-triiodo-L-thyronine was found to upsurge both NgB mRNA and protein levels to control levels in cortices, hippocampi, and cerebella 24 h after administration [79]. Higher mRNA levels were also detected at earlier time points, which did not correlate with still unaffected protein levels [79]. Such differences could be indicative for posttranscriptional processing of NgB or for NgB catabolism playing an important role in the regulation of its protein levels. By way of example, protein levels of HIF1 itself are mainly regulated by oxygen-sensitive prolyl hydroxylases, targeting HIF1 for ubiquitination and proteosomal degradation under normoxic conditions [80].

In addition, NgB is reported to be upregulated by and protective against Alzheimer's disease (AD) (Tables 1 and 2). AD brains exhibit a constitutive upregulation of Akt activation (p-Akt/total Akt ratio) [81], which could lead to *NgB* expression through the TSC1/2-Rheb-mTOR-HIF1 signaling pathway. This pathway could also contribute to NgB levels being transiently affected during AD progression, i.e. being only elevated in up to moderately affected AD brains [39, 82]. Where prolyl hydroxylases are keys to fine-tune protein levels of HIF1, microRNAs form an alternative mechanism for its posttranscriptional regulation. In particular, microRNA-155 expression is induced upon prolonged hypoxia, silencing HIF1 translation [83]. Interestingly, we recently showed *NgB* transcription to be downregulated in cortices and hippocampi of young APP23 mice subjected to whole body hypoxia [84], providing evidence for a key role in the downregulation of *NgB* transcription to be played by AD angiopathogenesis.

Mitochondrial functioning and autophagy in relation to cellular senescence and AD are other downstream processes of mTOR signaling [85]. Not only do NgB protein levels undergo an age-related decline under physiological aging [86], mitochondrial functioning and autophagy are cellular mechanisms to which NgB has been linked (Fig. 2). Moreover, NgB binds gamma-aminobutyric acid, which plays a key role in autophagosome formation [87]. NgB silencing also downregulates expression of *Entpd4*. The associated *Entpd4* protein participates in nucleotide turnover in the lysosomal-autophagolysosomal membrane [88]. Although indirect evidence suggests a link between the mTOR pathway and NgB, such a pathway of events remains to be studied. Regardless of the detection of a direct link between NgB and mTOR, reductions in NgB, with its cytoprotective properties, could contribute to the

Table 2 In vivo alterations and neuroprotective actions of Ngβ

Neurotoxic insult	Model	Ngβ mRNA	Ngβ protein	Neuroprotection	
AD					
28 days ICV Aβ ₁₋₄₀ solution (4.6 nmol/rat)	<ul style="list-style-type: none"> Male Wistar rats Cortical coronal sections 	n.d.	Ngβ ⁺ area 0.32% (1.85% in control)	n.d.	[38]
APP Swedish, Indiana mutation: K670N, M671L, V717F	<ul style="list-style-type: none"> 12-month-old Ngβ^{+/+}/APP^{Sw,Ind} double transgenics Brain sections 	n.d.	n.d.	<ul style="list-style-type: none"> 12 m: 1.8 ng/g Aβ₁₋₄₀ (32 ng/g in Wt) Normal somal microdomain distribution Restored performance in Y-maze 	[19]
APP Swedish double mutation: K670N/M671L	<ul style="list-style-type: none"> 13-month-old Tg2576 mice Brain sections and lysates 	n.d.	~3-fold ↓ as age-matched controls	Negative correlation between Ngβ and tau-P at pT231 and pS396 sites in neurons	[22]
APP Swedish + presenilin 1 (PS1-dE9) mutation	<ul style="list-style-type: none"> 13-month-old APP/PS1 mice, 1 mg/ml Ngβ-pCDNA3.1 ICV Brain lysates 	n.d.	n.d.	<ul style="list-style-type: none"> ~ Aβ₄₂: 105.9 to 79.5 pg/mg protein Better Morris water maze performance 	[21]
Pathologically confirmed AD	<ul style="list-style-type: none"> Mixed gender patients Superior temporal lobe 	23% higher in AD cases as in controls	n.d.	n.d.	[39]
Neuropathologies: AD, AGD and PD	<ul style="list-style-type: none"> Mixed gender patients HC, subiculum and dorsal nucleus of the vagus 	n.d.	≈ in neurons with and without tau or synuclein	n.d.	[40]
Combustion smoke inhalation					
<ul style="list-style-type: none"> Wood shavings 1 h: 5 min smoke, 10 s venting 	<ul style="list-style-type: none"> Male Ngβ^{+/+}-Tg mice Cerebrum 	Overexpression in cerebrum-cerebellum	Broadly distributed in mid-brain region	% inhibition of complex I	[41]
<ul style="list-style-type: none"> Wood shavings 1 h: 10 min smoke, 10–20 s venting 	<ul style="list-style-type: none"> Male Ngβ^{+/+}-Tg mice Cortical mitochondria 	n.d.	Detected on blots, not in those of Wt controls	<ul style="list-style-type: none"> 0 h: 92.5 ± 7.2 (78.2 ± 4.4 in Wt) 2 h: 76.7 ± 7.4 (53.2 ± 6.3 in Wt) 1 h: 25% less OCR reduction as Wt 24 h: lactate to baseline (↑60% in Wt) 24 h: 120% ↑c-Fos (250% in Wt) 	[42]
<ul style="list-style-type: none"> Cigarette smoke 15 min/d for 5 d/w 25 ppm CO in 22% O₂ 12 h/d up to age of 20 d 	<ul style="list-style-type: none"> Male Wistar rats (8 w) Cortex and HC Sprague-Dawley rats Cerebellum 	<ul style="list-style-type: none"> Cortex 1.1–1.4× ↑ HC 1.3–1.5× ↑ No significant change 	<ul style="list-style-type: none"> Cortex 1.2–1.4× ↑ HC 1–1.4× ↑ No significant change 	n.d.	[43]
Eye pathology					
<ul style="list-style-type: none"> Predisposition to eye abnormalities, progressive glaucoma 	<ul style="list-style-type: none"> DBA/2J mice (2 and 8 m), AAV2/2-Ngβ delivery Retina 	3.4/3.6-fold ↑ at 2/8 months as compared to untreated	Untreated: ↓ by age Treated: RGC 79% Ngβ ⁺ (2-fold ↑)	<ul style="list-style-type: none"> Decreased glial cell activation Protection against RGC loss Retinal morphology better preserved Neuronal activity in the visual cortex ↑ 3× more of surviving RGC (day 14) More than double # of regenerating axons as in control group 	[45]
Optic nerve injury	<ul style="list-style-type: none"> C57BL/6 mice (8/9 w), 5 μM human/zebrafish chimeric Ngβ Retina 	n.d.	Day 5: untreated (50% ↓), treated (50% ↑)	n.d.	[46]
Huntington's disease					
<ul style="list-style-type: none"> Huntingtin gene, carries approximately 120 ± 5 CAG-repeat expansions 	<ul style="list-style-type: none"> Male and female R6/2 mice (7 and 13 w) Striatum 	n.d.	<ul style="list-style-type: none"> ♂: ~2-fold ↑ as compared to Wt ♀: higher in Wt 	Ngβ protein mostly detected in neurons with large and medium perikarya	[47]
<ul style="list-style-type: none"> Huntingtin gene, carries approximately 125 CAG-repeat expansions 	<ul style="list-style-type: none"> Male and female R6/2 mice (4–13 w) Hippocampus 	n.d.	↓ by ~half in both female and male R6/2 mice	Mutant Huntingtin impairs 17β-estradiol- and BDNF-induced Ngβ expression and mitochondrial localization	[48]
Hypoxia					
1.5 h 7% O ₂ , 93% N ₂	<ul style="list-style-type: none"> Female Ngβ^{-/-} mice Brain lysates 	n.d.	n.d.	<ul style="list-style-type: none"> ↑ Hif1A, Csp1, Ad1, and Pp1f4b mRNA ↓ Ubc, Rplp0, and Kidins220 mRNA 	[49]
2 h 7.6% O ₂ , 92.4% N ₂	<ul style="list-style-type: none"> Female BALB/c mice Cerebrum, cerebellum 	<ul style="list-style-type: none"> Cerebrum: 1.1× ↑ Cerebellum: 0.7× ↓ 	No upregulation across brain	Expression only detected in neurons, e.g., Purkinje cells	[50]
5 h, 6% O ₂	<ul style="list-style-type: none"> Sprague-Dawley rats Whole brains 	<ul style="list-style-type: none"> ↓ to half the normoxic value 	Slight downregulation	n.d.	[51]
48 h 7% or 12% O ₂	<ul style="list-style-type: none"> Swiss CD1 mice Total brains 	<ul style="list-style-type: none"> 7 h: 1.95 ± 1.11 12 h: 3.23 ± 1.16 	n.d.	n.d.	[52]
≤ 48 h 7% O ₂ , 93% N ₂	<ul style="list-style-type: none"> Swiss CD1 mice 	<ul style="list-style-type: none"> 2, 4, 6, 12 h: = 	n.d.	n.d.	[11]

Table 2 (continued)

Neurotoxic insult	Model	Ngb mRNA	Ngb protein	Neuroprotection		
6 h 8% or 7 days 10% O ₂	<ul style="list-style-type: none"> ◦ Whole brains ◦ Neonatal C57BL/6 mice ◦ Whole brains ◦ Male C57BL/6 mice ◦ Whole brains ◦ Male Sprague–Dawley rats ◦ Cortex ◦ Male Sprague–Dawley rats ◦ Cortex ◦ Mixed gender cohort ◦ Hypoxic milieu within WML 	<ul style="list-style-type: none"> ◦ 12, 48 h: ↗ 7 days 10%: 2.01-fold ↗ Unchanged Sustained ↗ of ~2-fold the baseline Only slight ↗ at day 1 n.d. 	<ul style="list-style-type: none"> P0: Ngb⁺ ↗ in cortex P7: unchanged Unchanged Sustained ↗ of ~1.8-fold the baseline Only slight ↗ at days 1 and 3 # Ngb⁺ cells ↗ by ~10% 	<ul style="list-style-type: none"> Negative correlation between Ngb and H₂O₂ concentration n.d. n.d. n.d. n.d. Ngb expression in activated microglia 	[53] [54] [55] [55] [56]	
Ischemia	<ul style="list-style-type: none"> ◦ 10 min MCAO ◦ 3 days reperfusion ◦ 30 min MCAO ◦ 24 h reperfusion ◦ 1.5 h MCAO ◦ 4–24 h reperfusion ◦ 1.5 h MCAO ◦ 24 h reperfusion ◦ 1.5 h MCAO ◦ 24 h reperfusion ◦ 1.5 h MCAO ◦ 24 h reperfusion ◦ 45 min MCAO ◦ Up to 14 days reperfusion ◦ 12.5 min two-vessel occlusion ◦ 1–2 h deep hypothermic circulatory arrest ◦ 6 h reperfusion 	<ul style="list-style-type: none"> ◦ C57/B6, Ngb transgene under ubiquitin C promoter (10 w) ◦ Hippocampus ◦ BDF × CDI mice: beta-actin promoter for Ngb overexpression ◦ Whole brains ◦ Rats ◦ Cortex, penumbra, and core ◦ Male Sprague–Dawley rats, 0.72 nM Ngb oligodeoxynucleotide ◦ Cortex ◦ Male Sprague–Dawley rats, intracerebral AAV-Ngb ◦ Male C57BL/6 J mice, 10 mg/kg i.v. TAT-Ngb ◦ Brain hemispheres ◦ Spontaneously hypertensive rats ◦ Brain hemispheres ◦ Male hypertensive rats, CAV-2-Ngb transduced ◦ Cortex and striatum ◦ Male Wistar rats ◦ HC, cortex; dentate gyrus ◦ Neonatal piglet model ◦ Mixed gender cohort, 62 ± 12.8 years ◦ Superior temporal lobe ◦ Mixed gender; C57BL/6j;129/Sv ◦ Sagittal and coronal sections ◦ Male Sprague–Dawley rats ◦ Temporal cortex ◦ Male Wistar rats ◦ Whole brain lysates 	<ul style="list-style-type: none"> Transgene: 4-fold ↗ n.d. n.d. n.d. n.d. n.d. n.d. n.d. 24 h: lowered by ~40% n.d. No significant increases ◦ 1 h: unchanged ◦ 2 h: ↗ by ~half ◦ 180× ↗ as <i>ACTB</i> ◦ >1% per year n.d. Peaks at 6 h post-TBI: 3-fold ↗ 6/12/24/48 h: + 929/490/171/133% n.d. 	<ul style="list-style-type: none"> Transgene: 2.5-fold ↗ Increased intensity on western blot ↗ in cytoplasm of normal-appearing penumbritic neurons Lower intensity on western blot ↗ IHC intensity in cortical neurons n.d. 1 w: no difference with sham animals 19 days: 25% ↗ (9.9% in Wt) n.d. n.d. 	<ul style="list-style-type: none"> ◦ Unaltered SOD, GPX, catalase activity ◦ Ischemia injury ↗; i.e. lipid peroxidation, nitrotyrosine and ROS levels, cell death ◦ Overexpression: 30% ↗ infarct volume ◦ Cerebral blood flow is ≈ in Wt and transgenic mice n.d. ◦ Knockdown: 56–60% ↗ infarct volume ◦ Worsened neurological severity score ◦ 49–52% ↗ in the size of cerebral infarcts, primary in the cortex ◦ Improved neurological function ◦ Decreased infarct volume and cell death ◦ Improved neurological deficit scores 72 h after 30-min MCAO ◦ No difference in Ngb/NeuN ratio ◦ Inverse correlation: infarct volume and # Ngb⁺ neurons ◦ No effect on SBP or survival ◦ ↗ infarct size in motor cortex and striatum ◦ 14 d: less footfalls in tapered beam walk n.d. Neuronal cell necrosis correlates with neuroglobin Ngb expression ↗ Higher expression in rs8014408 carriers, but faster decrease upon aging n.d. Ngb positivity co-localizes for 98.9% with NeuN, otherwise Iba1 but not GFAP n.d. ◦ 1 day: +++ staining 	[57] [58] [59] [60] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70]
Normal aging	Neurologically normal subjects	<ul style="list-style-type: none"> ◦ 180× ↗ as <i>ACTB</i> ◦ >1% per year 	n.d.	Higher expression in rs8014408 carriers, but faster decrease upon aging	[66]	
TBI	<ul style="list-style-type: none"> ◦ Cryo-lesion in fronto-parietal cortex ◦ Subarachnoid autologous arterial blood injection ◦ 450-g weight drop from 2-m height ◦ Needlesick injury 	<ul style="list-style-type: none"> ◦ 1 h: unchanged ◦ 2 h: ↗ by ~half ◦ 180× ↗ as <i>ACTB</i> ◦ >1% per year n.d. Peaks at 6 h post-TBI: 3-fold ↗ 6/12/24/48 h: + 447/259/195/135 pg/mg ◦ 1 day: +++ staining 	<ul style="list-style-type: none"> Asrogliar: TBI edge (3 days) and within (10 days) ↗ up to 24 h after TBI and ↗ from 48 to 72 h after TBI 6/12/24/48 h: + 447/259/195/135 pg/mg ◦ 1 day: +++ staining 	<ul style="list-style-type: none"> n.d. Ngb positivity co-localizes for 98.9% with NeuN, otherwise Iba1 but not GFAP n.d. 	[67] [68] [69] [70]	

Table 2 (continued)

Neurotoxic insult	Model	Ngb mRNA	Ngb protein	Neuroprotection
<ul style="list-style-type: none"> ◦ 3-mm injury tip ◦ 6 m/s, 0.6 mm depth ◦ 3-mm injury tip ◦ 1.5 m/s, 1 mm depth ◦ 3-mm injury tip ◦ 1.5 m/s, 1 mm depth 	<ul style="list-style-type: none"> ◦ Mixed gender Sprague-Dawley rats ◦ Neocortex ◦ Ngn^{+/+}-Tg mice ◦ Cerebral cortex ◦ Male C57/BL6 mice ◦ Cortex and coronal sections ◦ Male B6.Cg-Tg (CAG-Ngb-EGFP)/Dgrm/J mice ◦ Cerebral cortex 	n.d.	<ul style="list-style-type: none"> ◦ 3 days: ++ staining ◦ 5–30 days: + staining 6 h: 196% of Wt shams 7 days: gliaheurons of HC/cortex 7 days: gliaheurons throughout the brain 	<ul style="list-style-type: none"> ◦ Decrease in Ngn level after injury is statistically significant ◦ ~ 3NT levels and brain lesion volume ◦ Unvaried sensorimotor/memory recovery ◦ Ngn reactivity is primarily found near the injury site ◦ Improved sensorimotor recovery ◦ 2 days: ~ 1.9 ft faults/min (~ 2.9 in Wt) ◦ 7 days: ~ 0.5 ft faults/min (~ 1.4 in Wt) ◦ ~ outcome in rs3783988 alleles (Wt: TT): ◦ 3 months: TT (30.3% good), CC/CT (14.0%) ◦ 1 year: TT (51.5% good), CC/CT (29.4%) ◦ Co-localization of Ngn with NeuN, but not GFAP
Severe TBI: hematomas-and hemorrhage-related	Caucasian patients	n.d.	n.d.	[71]
Intracerebral hemorrhage	Patients with cerebral arteriovenous malformations	n.d.	↗ in parenchyma adjacent to lesions	[72]

AD Alzheimer's disease, A β amyloid precursor protein, BDNF brain-derived neurotrophic factor, HC hippocampus, ICV intracerebroventricular, MCAO middle cerebral artery occlusion, Ngn neuroglobin, OCR oxygen consumption rate, PD Parkinson's disease, RGC retinal ganglion cells, ROS reactive oxygen species, SBP systolic blood pressure, TAT trans-activator of transcription, TBI traumatic brain injury, WML white matter lesions, Wt wild-type

age-related susceptibility to ailments of the neuronal system.

Neuronal Survival Linked Elements—REST, CREB

The *Ngn* promoter contains two RE1-silencing transcription factor (REST) sites –359 and –127 bp relative to the transcription start site [76]. REST activation is known to work neuroprotective, repressing proapoptotic genes [89]. Expression of *REST* is upregulated along physiological aging. This is, at least partly, attributed to canonical Wnt- β -catenin signaling, a pathway known for controlling cell proliferation and fate throughout development and adult life [89]. In cases of aggregation pathology, e.g. AD and frontotemporal lobar degeneration, REST appears trapped in cytoplasmic inclusions. Subsequent depletion of its nuclear levels entails the loss of downstream oxidative stress resistance and apoptosis counteraction ([89] Fig. 2). The latter may also contribute in the *Ngn* transcription upregulation, seen in early AD stage brains, to be lost when the AD pathology reaches end-stages [39, 82]. *REST* transcription is indeed detected to correlate with the one of *Ngn* in cortices of mouse models of β -amyloid pathology and hypoxia [84]. REST-mediated *Ngn* expression regulation could be extended to other etiologies in which cellular damage reaches a certain threshold as well, e.g. *Ngn* expression is upregulated after subacute and chronic traumatic brain injuries but not after an acute injury [90]. Of note, the 5'-flanking region of the *Ngn* gene comprises two CpG methylation islands from –874 to –600 and from –157 to +885 relative to the transcription start site [76]. As REST activation also influences histone acetylation modifications [89], it remains to be elucidated to which extend (de)acetylation and (de)methylation patterns influence *Ngn* expression upon different cellular conditions.

Incubation with 10 nM 17 β -estradiol (1 h) enriches the H3K4me3 epigenetic marker at the *Ngn* promoter site in SK-N-BE and NT2 differentiated cells [91]. The expression-enhancing, noncoding RNA transcript (chr14:77,735,963-77,736,462; hg19) in *Ngn*'s first exon gets marked by H3K4me1 and H3K27Ac as well [91]. Hence, *Ngn* could be one of the neuronal genes that are influenced by steroid hormones, i.e. 17 β -estradiol, which are known for their mitogenic, anti-apoptotic, and anti-inflammatory effects. A 24-h incubation with 1 nM 17 β -estradiol was detected to raise Ngn protein levels by 300% in SK-N-BE neuroblastoma cells and mouse hippocampal neurons [92]. Another study detected a 2- and 2.5-fold increase in SK-N-BE and NT2 cells at a higher concentration of 10 nM [91]. However, no (or almost no) Ngn reads could be identified in a recent RNA-seq study on the SK-N-BE cell line [6], putting the previous findings to the question. Other papers already pinpointed the need to consider the different detection methods and tissue preparations which are being used for Ngn quantification, as well as the




Fig. 2 *Ngf* expression regulation and downstream neuroprotective actions. *Ngf* is upregulated under different conditions of cellular stress, containing binding sequences for regulatory elements as AP1, CREB,

Erg1, NF1, NF- κ B, REST, and SP1/3. Once expressed, downstream functions of *Ngf* can be paralleled to known effects of the respective pathways

necessity to validate antibodies [93]. *Ngf* is indeed characterized by a low antigenicity and, as a result, the occurrence of antibody cross reactivity has been described before [94]. Discrepancies between *Ngf* transcript and protein levels have been detected as well [68, 79]. Given the above, it could be of interest to investigate the endogenous epigenetic status of *Ngf* in the different experimental setups, in addition to displaying extra vigilance on the used *Ngf* detection system.

The cAMP response element binding (CREB) protein is another transcription factor with a binding site in *Ngf*'s regulatory region [95]. CREB-mediated transcription is linked to ROS detoxification, vertebrate synaptic plasticity, and neuronal survival (reviewed in [96]). Of note, once transcribed, *Ngf* can induce a phosphorylation cascade, starting from Akt, which leads to CREB activation [38]. Hence, an elevated *Ngf* protein level could be sustained through such a positive feedback loop. The latter still has to be demonstrated experimentally.

Pharmacological Induction of *Ngf*—Hemin, Short-Chain Fatty Acids, Deferoxamine, Tibolone, Ibuprofen, (R)- α -Lipoic, Natural Plant Compounds

In light of the neuroprotective effects of elevated *Ngf* levels, different pathologies and injuries of the nervous system might benefit from therapeutically increasing intracellular *Ngf* levels. The most self-evident way to address *Ngf* levels would be a recombinant protein replenishment therapy, which is incompatible with *Ngf* being membrane impermeable. Hence, studies have been elucidating the potential of pharmacologically increasing *Ngf* levels, in which the use of pharmaceuticals with a blood-brain barrier (BBB)-crossing capacity would be most preferable.

Administration of hemin, an iron-containing porphyrin, forms part of the clinical management of porphyria attacks, which are characterized by gastrointestinal and neuropathic symptoms, and etiologically grounded in a dysfunctional

heme biosynthesis (OMIM #176000). When added to the culture medium of hippocampal HN33 cells, 50 μ M hemin increases both *Ngf* transcript and protein levels up to 4-fold. The expression is regulated by sGC-PKG signaling [97], an upstream effector of vesicle cycling, actin remodeling, and neurite outgrowth.

HN33 cells were detected to have increased their *Ngf* protein level 5 to 14-fold above control levels when grown in valproic acid and cinnamic acid containing medium, respectively. Though the mechanism of action is still unclear, the *Ngf* expression inducing effect of both short-chain fatty acids is unlikely caused by histone deacetylase inhibition [98]. Of note, valproic acid is the active compound in a variety of anticonvulsant drugs, primarily used in the treatment of generalized and partial epilepsy. Cinnamic acids (derivates), on the contrary, are being investigated as histone deacetylase inhibitors for the treatment of solid tumors and hematological malignancies (e.g., registered at www.clinicaltrials.gov as NCT01496118, NCT01451268). Hence, these therapeutic indications are less in accordance with those in which *Ngf* has been detected to have a beneficial effect (Tables 1 and 2).

Ngf transcription in primary mouse cortical neurons is elevated by 100 μ M deferoxamine [59]. This chelating BBB-crossing agent has therapeutic indications that include chronic iron overload (genetic or acquired hemochromatosis, OMIM #235200), acute iron intoxication, and chronic aluminum overload in end-stage renal failure. The chemical works through the activation of hypoxia-inducible genes, such as HIF1 [59]. Another molecule is Tibolone. This synthetic BBB-crossing steroid works through complex formation with SP1 downstream of HIF1 [99]. It has a clinical efficacy in the prevention of osteoporosis and the relief of the symptoms related to estrogen deficiency. Interestingly, it has important neuroprotective effects on the central nervous system as well [100]. This raises the question as to whether *Ngf* upregulation could be in part attributing to these effects. When administered at 10 nM to primary cortical cell cultures of mice, *Ngf*

expression levels increase ~1.8-fold [101]. The latter is increased to ~2.5-fold when combined with oxygen-glucose deprivation (OGD), an increase that is also observed on the protein level. Of interest, *Ngb* silencing prevents tibolone's support of cell survival under OGD, with cells losing their mitochondrial membrane potential [101].

CREB-linked *Ngb* transcription can be targeted by natural compounds as formononetin, providing protection against OGD-induced neurotoxicity in primary neuronal cultures [102]. In addition, given the cell survival characteristics of CREB and *Ngb*, an ibuprofen and (R)- α -lipoic acid conjugate was developed as to combine the known AD-ameliorating effects of both components and as to study the molecular events attributed to *Ngb* activation. Subcutaneous administration of the conjugate to AD rats (250 μ L/kg) results in their brains maintaining *Ngb* levels to healthy control levels, even at vast amounts of intracerebroventricular A β (1–40). Moreover, the sustained *Ngb* levels correlate with less apoptosome formation and cell death [38].

Another fusion molecule, Tat-*Ngb*, was created, making recombinant *Ngb* cell- and possibly BBB-permeable. The protein, produced by *Pichia pastoris*, was found to increase *Ngb* levels in pheochromocytoma PC12 cells and, as such, to avert hypoxia-linked cellular damage [103]. Nonetheless, *Ngb* might have some cytoprotective effects in the periphery as well. Azarov et al. engineered human *Ngb*-H64Q-CCC, which is 1200 faster in displacing CO from carboxyhemoglobin in comparison to when only atmospheric oxygen is present [104]. Intravenous infusion of CO-poisoned mice with the *Ngb* ligand trap antidote increases their survival rate to 87.5% as compared to less than 10% in control mice. With CO-bound *Ngb*-H64Q-CCC to be detected in the mice's urine, this approach also appears promising with regard to safety of therapy [104].

Given the different transcription factors with a known link to neuroprotection regulating the expression of *Ngb*, the notion is underscored of *Ngb* being involved in the preservation of nervous system homeostasis.

Ngb Modes of Action

Constraint and Use of Oxidative Molecules

An essential element in the understanding of *Ngb*'s functions and mechanisms of action lies in its unique structure. The eight alpha helices (3'-A-B-C-D-E-F-G-H-5') of *Ngb*'s secondary protein structure are stacked in the classical three-over-three alpha-helical fold to generate a three-dimensional hydrophobic pocket for the central heme iron atom [12, 105]. A structural deviation from other globins, such as hemoglobin and myoglobin, lies in *Ngb*'s wide protein core cavity and its structural flexibility encompassing the C and E helix regions


[105]. The latter enables the sixth position of the *Ngb* heme iron to reversibly coordinate with either an external ligand (hexacoordinated), the HisE7 residue (hexacoordinated) or being unbound (pentacoordinated) [10, 12]. Hence, an external ligand as O₂ or nitric oxide (NO) can only bind the heme atom after disruption of the iron-HisE7 bond, a process of which the kinetics are strongly influenced by the redox state of the internal *Ngb* CysCD7-CysD5 disulfide bond [106–109]. By way of example, the k_{on} of CO and O₂ shifts from 40 and 140 μ m⁻¹ s⁻¹ to 50 and 170 μ m⁻¹ s⁻¹ after disulfide bridge disruption, respectively [106].

Both cysteines lie at the internal cavity in the CD loop region, linking the C and D helices of the globin fold [9, 110]. The importance of the intramolecular disulfide bond is represented by the position of both cysteine residues being remarkably conserved [110]. Such conservation is grounded in the cysteine bridge being able to translate the redox state of the cell into differential ligand affinities (binding and release) by controlling the heme iron coordination (hexa \leftrightarrow penta) (Fig. 3). Electron transfers induce conformational changes of the imidazole planes of the heme pocket, completing the transitioning between the reduced (*Ngb*_{SH}) and oxidized (*Ngb*_{SS}) states [106, 111]. Hence, it may be of no surprise that *Ngb* is also detected in cellular compartments which set the redox environment of the cell. Where generally the vast majority of the cellular *Ngb* content is detected within the cytosol, different studies also describe a *Ngb* mitochondrial pool to be present under different cellular conditions [27, 34, 112, 113]. The mitochondrial *Ngb* fraction ranges from near 8% in primary mouse cortical neuron cultures [34] to 70% in retinal neurons of the rat [27], even though *Ngb* lacks a mitochondrial signaling sequence.

Ngb exerts both a nitrite reductase function and a NO dioxygenase activity (Fig. 3). Hence, *Ngb* plays an important role in adapting NO levels to the cellular state. NO has beneficial effects under oxygen depletion. It evokes hypoxic vasodilation and reversibly inhibits cytochrome oxidase, limiting mitochondrial respiration and ROS production [114]. Interestingly, in case of oxidative stress, the cellular environment will favor the oxidized state of *Ngb*. *Ngb*_{SS} generates NO at a rate (k of *Ngb*_{SS} = 0.12 ± 0.02 m⁻¹ s⁻¹) that is close to 2-fold higher as to when the disulfide bond is reduced (k of *Ngb*_{SH} = 0.062 ± 0.005 m⁻¹ s⁻¹) [115]. The production of NO is further promoted by ERK1/2 and PKA activation upon hypoxic and ischemic insults. Both kinases have docking sites on *Ngb* (amino acids 17/19/50/51) and subsequent phosphorylation increases *Ngb*'s nitrite reductase activity up to 4-fold the nonphosphorylated level [116]. Phosphorylation also facilitates the binding of 14-3-3 scaffold proteins, which counteract dephosphorylation by phosphatase activity [116].

However, excess of NO needs to be detoxified. NO interacts with superoxide to form peroxynitrite, which generates strong nitrating agents together with CO₂. Being located in the

Fig. 3 Impact of the cellular redox state on (neuro)protective functions of Ngb. The CysCD7-CysD5 disulfide bond is indicated as present (S-S) or absent (depicted with reduced sulfhydryl -SH groups). Hexacoordinated Ngb interacts with mitochondrial voltage-dependent anion channels (VDAC), counteracting the release of apoptotic cytochrome c. Ferric (Fe^{3+}) Ngb, e.g. formed after the reduction of ferric cytochrome c, is recruited to lipid rafts by binding to flotillin-1. The interaction opposes the activation of α -subunits of heterotrimeric G proteins ($\text{G}\alpha$) by acting as a guanine nucleotide dissociation inhibitor. Preventing cellular cAMP levels to drop adds to neuroprotection. The oxidation state of Ngb further contributes in the scavenging and detoxification of reactive oxygen and nitrogen species



vicinity of mitochondria and within, Ngb appears to be an ideal candidate scavenger. Ferric (Fe^{3+}) Ngb can bind NO following bi-exponential kinetics ($6.6 \pm 0.5 \times 10^{-3}$ and $2.0 \pm 0.1 \times 10^{-3} \text{ s}^{-1}$). This generates a thermodynamically stable ferrous (Fe^{2+}) Ngb-NO species by reductive nitrosylation [14]. Once bound, NO initially shields the ferrous iron from (auto)oxidation [108]. For Ngb's NO dioxygenase activity, the globin contains multiple docking sites in which gaseous ligands can bind for up to several hundred microseconds before sequential reactions take place with the central heme atom [7]. The reaction could exist in a synergism with the scavenger activity of ferric Ngb against superoxide, which was detected to have a IC_{50} value of $7.4 \pm 0.7 \mu\text{M}$ ([16] Fig. 3).

Cell Life and Death Decisions

Mitochondria are not only key players in cellular ATP production, providing in the high energy demand of neurons, they also initiate or contribute in the apoptosis process when cellular damage accumulates. The notion of Ngb playing an important role in the counteraction of cell death is consistent with Ngb's significant redistribution to the

mitochondria upon OGD [34, 117]. Although the ratio of mitochondrial Ngb to the total intracellular Ngb level only slightly increases from 7.8% in healthy neurons to 9.9% upon OGD, this increase represents a significant 2.1-fold increase of mitochondrial Ngb [34]. Of interest, Ngb-interacting partners have been studied before, some of which are mitochondrial proteins involved in apoptosis (Table 3). One of these proteins is the voltage-dependent anion channel (VDAC) ([87] Fig. 3). VDAC is an important regulator of ATP- and Ca^{2+} transport, which spans the mitochondrial outer membrane. In cases of oxidative stress, superoxide initiates the fast release of cytochrome c through VDAC-dependent permeabilization [124]. Hence, Ngb is proposed to oppose neuronal apoptosis by its binding to VDAC, blocking the discharge of cytochrome c into the cytosol. Furthermore, VDAC blockers (DIDS and dextran sulfate) inhibit OGD-induced Ngb translocation to the mitochondria. Inhibition of the mitochondria permeability transition pore (mPTP) was detected to have a similar effect on mitochondrial Ngb transport [34]. Knowing mPTP activation to be linked to events of late apoptosis and necrosis, including matrix swelling

Table 3 In literature-described Ngb-protein interactions

Ngb binding partner	Cellular location	Model(s)	Identification	Validation	Ref.
14-3-3 protein	Cytosol	SH-SY5Y cells, brainstem and thalamus of sheep HEK293	Co-IP - WB	FRET analysis	[116]
Casein kinase 2, alpha prime polypeptide	Cytosol, nucleus, plasma membrane		Co-IP - MS	Cross-laboratory comparison	[118]
Cystatin C	Extracellular, cytosol, ER	Yeast, recombinant proteins	Y2H screen	SPR analysis	[119]
Cytochrome C1	Mitochondrion, nucleus	Yeast, primary mouse cortical neurons	Y2H screen	Co-IP - WB	[87]
Cytochrome B5, C	ER, extracellular, mitochondrion, cytosol	Primary mouse cortical neurons	IHC co-localization	Co-IP - WB	[117]
Disheveled homolog 1	Cytosol, nucleus, plasma membrane	Recombinant proteins	Absorbance spectrum	Kinetic traces	[17]
Electron transferring flavoprotein α subunit	Extracellular, mitochondrion	Yeast, primary mouse cortical neurons	Y2H screen	Co-IP - WB	[87]
Flotillin-1	Cytosol, plasma membrane	Yeast, primary mouse cortical neurons	Y2H screen	Co-IP - WB	[87]
GABA _A receptor-associated protein-like 1	Cytosol, ER, Golgi	Yeast, primary mouse cortical neurons	Y2H screen	GST pull-down - WB	[120]
Heterotrimeric G protein α subunit	Plasma membrane, lysosome, cytoskeleton	Primary mouse cortical neurons	Co-IP - WB	Co-IP - WB	[87]
Huntingtin	Cytosol, nucleus	Recombinant human Ngb	SPR analysis	Functional assays	[122]
Microtubule-associated protein 1	Cytosol, cytoskeleton	SK-N-BE cells	Co-IP - WB	Proximity ligation assay; Duolink	[48]
Na/K ATPase β 1,2,3	Plasma membrane	Yeast, primary mouse cortical neurons	Y2H screen	Co-IP - WB	[87]
P21 (RAC1) activated kinase 1	Cytosol, Golgi, membranes	Yeast, primary mouse cortical neurons	Y2H screen	Co-IP - WB	[87]
Synaptotagmin I	Plasma membrane	Primary mouse cortical neurons	Co-IP - WB	Functional assay	[121]
Thioredoxin reductase	Cytosol, extracellular, nucleus	Yeast, primary mouse cortical neurons	Y2H screen	Co-IP - WB	[87]
Ubiquitin C	Cytosol, extracellular, nucleus	Recombinant proteins	Absorbance spectrum	MS	[123]
Voltage-dependent anion channel 1	Mitochondrion, nucleus, plasma membrane, cytosol	Yeast, primary mouse cortical neurons	Y2H screen	Co-IP - WB	[87]

ER endoplasmic reticulum, FRET fluorescence resonance energy transfer, GFP green fluorescent protein, GST glutathione S-transferase, IHC immunocytochemistry, IP immunoprecipitation, MS mass spectrometry, Ngb neuroglobin, SPR surface plasmon resonance, WB western blot, Y2H yeast two-hybrid

[125], it is questioned whether Ngb might be involved in those processes in some or other way as well. In support of this idea, Ngb overexpressing SH-SY5Y cells are protected against Ca^{2+} influxes and increases of cellular uptake of Fe, Cu, and Zn, associated with hypoxia-reoxygenation injury [30].

Of the cytosolic Ngb fraction, a chief part has been detected in close proximity with mitochondria [126]. During hypoxic events, Ngb protects against the formation of a lipid raft-mitochondrial-actin cytoskeletal lattice death signal by opposing Pak1 kinase activity, reducing Rac1-GDP dissociation, and the inhibition of actin assembly [121]. When localized in such mitochondrial vicinity, Ngb is also thought to prevent leaked ferric cytochrome c to interact with apoptotic protease-activating factor-1 (Apaf-1) and, hence, its oligomerization into an Apaf-1 apoptosome. Such impediment is achieved by ferrous Ngb being able to reduce ferric cytochrome c very fast ($k = 2 \times 10^7 \text{ M}^{-1} \text{ s}^{-1}$) [17]. A cytochrome reducing role for Ngb is further supported by the redox potential of cytochrome c, which is more positive as the one of Ngb [127]. Of note, in order to inactivate more than one cytochrome c, ferric Ngb is to be reduced back to its ferrous form. Such a reductase has not yet been identified (Fig. 3).

Ferric Ngb also exerts a pro-survival function, evinced by its recruitment to lipid rafts by binding to flotillin-1 [120, 128]. The interaction is not carried out by ferrous ligand-bound Ngb [120, 128]. At the membrane, it is proposed that ferric Ngb counteracts ROS-induced activation of α -subunits of heterotrimeric G proteins, acting as a guanine nucleotide dissociation inhibitor. The subsequent maintenance of cAMP levels contributes to cell survival [128]. Glu53, Glu60, Arg97, Glu118, and Glu151 residues of Ngb are crucial for this interaction [129]. It is also reported that Ngb interacts with Na/K-ATPase subunits, of which the function reaches further than the establishment of concentration gradients. Na/K-ATPase can form a functional complex with Src family kinases, leading to downstream effects on the Ras/Raf/ERK1/2 cascade and mitochondrial ROS production [130, 131]. However, a direct link between Ngb and this pathway remains to be shown.

Consideration should be given to the fact that the chronic inhibition of apoptosis paves the way for malignancy. To circumvent chronic promotion of tumor formation, only ~30% of the neuronal Ngb fraction is present in the anti-apoptotic ferrous state [132]. In case of lowered oxygen concentrations (e.g., as seen in stroke), oxygen quickly dissociates from the previously oxygenated form (dissociation rate constant of 4 s^{-1}) [132]. Reduction equivalents ($\text{NADH} + \text{H}^+$) further accumulate within the cell, making Ngb to potentially function as an oxidator of NADH to increase ATP generation by glycolysis [133]. The latter could contribute to the observation of a readjusted redox cycle towards the active hexacoordinated Ngb_{SS} form of the protein (to ~80% of the

cellular Ngb content), and this in a seconds time scale ([106, 132] Fig. 3). Moreover, Ngb levels need to outweigh those of Apaf-1, having both proteins binding to the same docking site on the cytochrome c surface [134]. Quantitative modeling even revealed the requirement of a high stoichiometric ratio of Ngb/cytochrome c to fully constrain apoptosis initiation [134]. The latter is in accordance with the significant increases of Ngb expression under neuronal stress (Tables 1 and 2). Hence, Ngb should be regarded as a protein that augments the threshold for apoptosis initiation rather than one that completely averts cell death.

Cancer cells, however, are known to circumvent cell cycle control [135] and to evade immune surveillance [136]. Hence, it is not unthinkable that, if of physiological relevance, malignant cells also dysregulate Ngb's biology in their advantage, i.e., as part of their triad of defense mechanisms against cell death and the hypoxic tumor environment. *Ngb* expression is indeed found upregulated in some squamous cell carcinomas, adenocarcinomas [137], and glioblastomas [24, 138]. The ectopic activation of *Ngb* expression, however, does not appear to be a classic constituent of malignancy. No Ngb upregulations were detected in a wide screening on samples of Burkitt's lymphoma, lymphoblastic leukemia, melanoma, glioblastoma, and astrocytoma [139]. Hence, increased *Ngb* transcription could be rather attributed to a specific tumor environment as to tumor types. In support of this idea, Ngb levels were found to be upregulated in MCF-7 breast cancer cells upon addition of ROS inducers as hydrogen peroxide and lead(IV), but to be unaltered in a PO_2 of 2%, representing the medium hypoxic tumor microenvironment [140]. Moreover, a better comprehension is needed on whether and/or how Ngb upregulation is contributing to the impediment of malignant cell eradication. In line with this indistinctness, Ngb levels have been detected to be upregulated in SK-N-LP neuroblastoma cells upon treatment with anti-cancer agents of the di-2-pyridylketone thiosemicarbazone series [141]. These compounds are highly potent copper chelators, inhibiting neuroblastoma growth [141]. In this case, elevated Ngb levels do not impact cell death. On the other hand, increased levels of Ngb have been detected to negatively influence the sensitivity of MCF-7 breast cancer cells to the active chemotherapeutic agent paclitaxel (Taxol) [142]. The latter acts through inhibition of microtubule depolymerization, opposing the dynamic reorganization of the microtubule network during mitosis.

Implication of Ngb on Astrocytic Inflammatory and Pro-Healing Pathways

Consensus has not yet been reached on astroglial expression of *Ngb*. Though Ngb was detected in primary cultures of murine cortical astrocytes and in human T98G astroglial cells [101, 143], positivity was not detected in glioblastoma cell

lines (DKMG, GAMG) [144], in astroglia across the adult subventricular zone of rats [145] or in astrocytes of whole mouse brain sections under control conditions [86]. Given the fact that culturing of astrocytes can endorse cellular stress due to the culture conditions or the disruption of process extensions [27], it was hypothesized that resting astroglia express negligible levels of *Ngb*. As for neurons, transcription could be increased in regions with or in the proximity of cellular damage. In addition to cell culturing conditions, the latter includes traumatic brain injury [31, 67, 72], metabolic stress [146], cerebral malaria, and autoimmune encephalitis [67]. *Ngb*-expressing astroglia are also linked to tolerance towards chronic environmental hypoxia as found in brains of aquatic mammals and the subterranean mole rat *Spalax* [51, 147]. Moreover, where neuronal transcription of *Ngb* returns to baseline after the insult [69, 70], *Ngb* immunoreactive astrocytes persist up to 12 months after brain trauma in patients [90]. The latter is in accordance with astrocytes playing an important role in the maintenance of homeostasis in neural tissue, regulating glutamate transport and neuroinflammation, and releasing neuroprotective molecules [148]. One of these restorative and protective molecules is the platelet-derived growth factor subtype BB. The latter was shown to also up-regulate *Ngb* expression in T98G astrocytic cells [149]. Even in cases of cellular stress, not every study so far has observed a link between *Ngb* and astroglia. Astroglial *Ngb* immunoreactivity was not detected in white matter lesions of a postmortem cohort [56], hypoxic murine brains [50, 68], and in ischemic stroke tissue of patients [150]. Dissimilarities could be the result of experimental differences, including the antibodies used, as mentioned earlier. The induction of astroglial *Ngb* expression could also be constraint to specific tissue regions and/or insults. A recent meta-analysis study of Fabrizio et al. indicated conserved patterns of *Ngb* expression, i.e., high- and low-expressing cells and tissues [6].

Irrespective of whether or not astroglia express *Ngb*, *Ngb* could indirectly effectuate changes in astroglial functions. When looking at neuron-specific AAV2-mediated overexpression of *Ngb*, mRNA levels of the glial fibrillary acidic protein (GFAP) are reduced by 19% in a murine model of Wallerian degeneration [151]. Knowing increased *GFAP* expression to be a hallmark of reactive astrocytes, it can be presumed that a *Ngb*-associated anti-inflammatory environment contributes to the observed preservation of axons [151]. *Ngb* silencing also impairs the reduction of the lipopolysaccharide-induced expression of the universal astroglial marker vimentin [31]. To boost neuronal regeneration and anti-apoptotic mechanisms, injury-induced astroglia characteristically produce transforming growth factor beta 1 (TGF- β 1) [152]. Given the link with functions associated with *Ngb*, the synergism between TGF- β 1 and *Ngb* has been investigated in postmortem cortical tissue of depressed and nondepressed individuals. A significant change was found for neither of the molecules

[153]. Hence, the white matter lesions and ischemia associated with depression might be of a too low severity for *Ngb*'s neuroprotection to act.

Finally, an anti-inflammatory effect associated with *Ngb* increases could not be limited to astroglia. Glial Müller cells increase their *Ngb* content above the one of resting cells as a response to retinal injury [154]. Moreover, postmortem tissue with white matter ischemia shows *Ngb* to be colocalized with microglial CD68 [56]. *Ngb* was also found in Iba1-positive cells in a rat model of subarachnoid hemorrhage [68]. The anti-inflammatory, regenerative effect could be a conjunction between actions of different cells as well. Culture medium of human adipose tissue-derived mesenchymal stem cells (2%) upsurges the transcription of *Ngb* by 251% in human astrocyte T98G cells upon mechanical injury and glucose deprivation [155]. The subsequent protective effect is abrogated when *Ngb* expression is silenced: reducing the mitochondrial membrane potential, lowering mitochondrial mass, and upsurging both superoxide and hydrogen peroxide levels [155]. In addition, transgenic overexpression of *Ngb* in a mouse model of acute myocardial infarction attenuates the expression of inflammatory markers in infarct border tissue, i.e. of *HIF1*, *ICAM1*, and *VCAM1* [156].

Neurogenesis, Improving Brain Integrity

Like most tissues, the nervous system contains stem cells which, through amplification and differentiation, are capable of replacing damaged and/or aged cells [1]. Hence, the observed ameliorations in tissue integrity upon *Ngb* expression induction (Table 2) could be attributed to not only an enhanced cell survival of existing cells but also to a boosted cell proliferation and differentiation as well. Of interest, neuronal stem cells in the subventricular zone of adult rats show a clear *Ngb* immunoreactivity [145]. Transcription factors SOX-3 and SOX-4, both associated with the preservation of the progenitor neuronal cell pool, are also cotranscribed with *Ngb* in the neurogenic subventricular zone [157]. Moreover, the expression appears correlated to the differentiation state of the cells. Where the *Ngb* levels are barely noticeable in embryonic stem cells, the *Ngb*/actin density ratio increases to 0.10 in neuronal stem cells and is still further elevated by about 40% in neuronally differentiated neuronal stem cells [145]. Mouse *Ngb* transcript levels further increase steadily from embryonic brains over newborns to a yield which is the highest in young adult brain [6]. The inverse relationship is observed when looking at nonneuronal cells as peripheral blood hematopoietic stem/progenitor cells. *Ngb* protein levels are 2-fold higher in uncommitted hematopoietic stem/progenitor cells (CD34^{high/bright}) as in more mature ones (CD34^{low}) [158]. These results are in accordance with a role for *Ngb* in the maintenance of the stem cell pool and with *Ngb* playing an even more pronounced role in neuronal

differentiation, but not in the differentiation of other cell types. Accordingly, GATA2 binding to its transcription factor binding site upstream of the human *Ngb* gene was identified to increase *Ngb* transcription [159]. Hence, *Ngb* might take part in known effects of GATA2 activation, being migration and differentiation of immature neuronal precursors [160, 161]. The gene neighborhood of *Ngb* also contains other conserved vertebrate transcription factor binding sites linked to neuronal cell fate and development (AP2 α , Churchill, INSM1, Klf4, REST) [162]. Developmental regulation was already described for two other globins, i.e. hemoglobin [163] and myoglobin [164].

Basal ganglia and parietal lobes of patients with intracerebral hemorrhage exhibit increased levels of proliferation and neuronal stem cell markers involved in neurogenesis [165]. A role may be reserved for *Ngb* in this tissue repair process. Perihematomal neurons and those adjacent to unruptured arteriovenous malformations show an enhanced immunohistochemical staining of *Ngb* [74]. In line with a role for *Ngb* in neurogenesis, a main part of the cellular *Ngb* fraction is present in axons and dendrites during neuronal development [166]. This localization is associated with neurite outgrowth. *Ngb* silencing in N2a cells reduces the length of neurites to 0–20 μm in over 70% of the cells [166]. On the other hand, overexpression of mouse *Ngb* significantly enhances neurite outgrowth in RGC-5 cells [167]. An underlying mechanism is found in *Ngb* levels positively correlating with elevated Akt (Ser473) and downscaled PTEN (Ser380/Thr382/Thr383) phosphorylation levels [166].

Considerations of Cell Lineage and Phylogeny

It is very important to choose the correct model for analysis of *Ngb* levels and functions. Some variation has been detected in *Ngb* transcription as a response to stress signals, e.g., on whether *Ngb* expression is increased [11, 53, 75], unaltered or decreased [50, 65] upon hypoxia. These results could be attributed to the expression of *Ngb* being strongly influenced by (I) the kind and degree of cellular stress, (II) the maturational stage of the cell or organism, and (III) the type of cell and organism.

Ngb transcription is indeed upregulated under moderate traumatic brain injury [90] and early-stage AD pathology [39, 82] but returns to baseline when cellular damage increases in both models. An important factor in such downregulation could be the loss of REST as a *Ngb* expression regulatory element. REST can get trapped within the cytosol through interaction with pathological misfolded proteins, including A β [89], and is downregulated by hypoxia-induced miRNAs [168]. The total degree of cellular dysregulation could function as some threshold for *Ngb* involvement as well. In support of this idea, *Ngb* expression correlates with

the level of cell death (necrosis and apoptosis) in a neonatal piglet model of deep hypothermic circulatory arrest [65]. Cortices with less than 10% necrosis stably express *Ngb*. In cases of high-grade (> 50%) neuronal cell necrosis, *Ngb* transcription is reduced by approximately half [65]. Moreover, while *Ngb* is ~ 6 times upregulated in P0 whole mouse brains after 6 h of 8% oxygen, the expression stays unaltered after a chronic exposure to 10% oxygen of 7 days [53]. The window of *Ngb* involvement appears to have a lower limit as well. Adult Swiss CD1 mice show a significantly increased *Ngb* transcript level after 24 and 48 h of 7% O₂, but not yet after 2 up to 12 h of hypoxia [11]. A similar *Ngb* expression profile is seen in HN33 cells that are exposed to 1% O₂, i.e. only a significant upregulation is detected as from 24 h hypoxia [64]. Additionally, where *Ngb* expression responds to sustained hypoxia (10% O₂), no effect is seen after an insult of intermittent hypoxia of 10% O₂ every 90 s [55]. Such stress type-dependent upregulation of *Ngb* is not limited to terrestrial animals, with the freshwater turtle *Trachemys scripta elegans* showing increased *Ngb* protein levels to $416 \pm 14\%$ of the control level after 4 h of hypoxia at 5% O₂ [26]. In case of a 4 h anoxic insult, *Ngb* protein levels are only elevated by $246 \pm 10\%$ over normoxic controls [26]. The zebrafish (*Danio rerio*) does not increase its *Ngb* transcription when subjected to mild hypoxia (PO₂ = ~ 8.6 kPa) for 48 h. Under severe hypoxia of 4.1 kPa PO₂, *Ngb* expression is four times elevated after 24 h but is almost returned back to baseline level after 48 h [169].

An age-dependent *Ngb* expression is detected across different studies as well. Mouse cerebral *Ngb* expression increases along the aging process up till its highest level is reached in young adults [6]. A similar trend is seen in the human carotid body in which the *Ngb*⁺ area on histology increases from $1 \pm 1.8\%$ in children of 2 years to $4.4 \pm 2.8\%$ in pensioners with a mean age of 73.5 years [170]. Age does also impact *Ngb* transcription under stress conditions. Cerebral *Ngb* mRNA concentrations are increased 6-fold in newborn mice subjected to an acute model of systemic hypoxia (8% O₂, 6 h). At P6, the *Ngb* transcript levels do not significantly differ from those of the normoxic controls [53]. A study on Wistar rats detected a *Ngb* expression induction in carotid bodies at the age of 3 months after 10–12% oxygen for 12 days. However, Wistar rats of 24 months did not show a significant upsurge in *Ngb* transcription after the hypoxic insult [171]. It is noted, however, that the different studies cannot be compared between one another as different kinds or levels of insults are studied, in addition to the use of diverse model systems and tissues.

Some organisms and cells are indeed better evolutionary adapted to certain types of stressors as others, being a third reason as to why differences in *Ngb* expression and functions are observed. By way of example, the human brain will develop irreversible brain injury after 5 to 10 minutes of oxygen

depletion while aquatic mammals as Weddell seals do not encounter neurological deficits after dives of over 1.5 h [172]. Ngb, as one of the resident neural globins, could be one part of the adaptation mechanisms. Goldfish (*Carassius auratus*), which live in isolated ponds with low oxygen partial pressures, have Ngb protein levels that are five times the level of zebrafish [173]. Ngb protein levels of coastal marine animals (e.g., the sea lion, sea otter, and bottlenose dolphin) are 1.7–1.9-fold higher as those of terrestrial animals [172]. Here too is a limit observed with regard to the neuroprotective effect of Ngb, with an inverse relationship existing between resident neural globin levels and maximum dive duration [172]. A basal elevated *Ngb* expression due to adaptations to extremely hypoxic/hypercapnic conditions could also explain the different *Ngb* expression patterns observed in such animals under hypoxic conditions. The subterranean mole rat *Spalax* has up to 2.8- and 3.5-fold higher transcript and protein levels as the rat under 21% O₂, respectively [51]. Given such a condition to represent an abnormal environment for the *Spalax* mole, the latter can be regarded as a stress condition with an excessive ROS production as a result of the higher as normal oxygen level. This is in line with the observed downregulation of Ngb mRNA levels to 40–75% of the normoxic condition after 22 and 44 h of 10% O₂, which is similar as the Ngb transcript levels of the rat under 21% O₂ [51]. A similar trend is seen in total fish preparations of the Japanese ricefish medaka (*Oryzias latipes*), showing a decrease in Ngb transcript levels after 24 and 48 h of PO₂ = 4 kPa [174]. However, brain samples alone showed an increase in Ngb transcripts, though significance was not reached [174].

It can be deduced from the foregoing that Ngb ligand affinities and functions differ between organisms throughout the phylogenetic tree; in particular, Ngb's structure and functions can be adapted to the specific circumstances and environmental requirements of the organism in which it resides. It is not only necessary to reflect on this when choosing a model system, but one can as well directly derive information from it regarding sequence-structure-function correlations. By way of example, gene orthologs of vertebrate Ngb are detected in organisms without a nervous system (e.g., placozoans) [162]. Hence, Ngb will exert more basic cellular functions within these organisms as compared to in higher order animals, in which its transcription is restricted to specific (neural) cell types. Such functional diversification was enabled through whole-genome duplication events in the stem lineage of vertebrates [175]. Indeed, with the increasing size of animals and the emergence of blood circulatory systems, vertebrate hemoglobin arose from co-option of duplicated *Ngb* genes [176]. Functional diversification can also be retrieved from phylogenetic footprinting. As such, neuron-specific expression of *Ngb* might be promoted by Klf4 and REST of which the binding sites around *Ngb* are conserved in vertebrates, but are not detected in or around other globin genes

[162]. Many other excellent additions on phylogenetic analyses of Ngb were excluded here as they went beyond the scope of the present review. The reader is directed to Ascenzi et al. [177] and Burmester et al. [3] for comprehensive reviews of the topic.

Discussion and Future Perspective

Our understanding of Ngb's genetics, structure, evolution, and biological functions has greatly increased over the last decade. Given the positive correlation between Ngb levels and beneficial outcomes in numerous ailments (Table 2), the notion is underscored of Ngb having cytoprotective traits. While the focus was first on intrinsic neuroprotective contributions of Ngb (i.e., the reduction of proapoptotic cytochrome c [17], Ngb's nitrite reductase activity [115], and its scavenger activity against superoxide [16]), the research field is now starting to move to studying the involvement of Ngb in signaling pathways in neuronal and nonneuronal cell populations [69, 70, 166].

To obtain such biological insights, it might be required to study Ngb^{-/-} mice or other model organisms. So far, most studies on Ngb have been on *Ngb*-overexpressing transgenic mice [19, 41, 58, 178]. While *Ngb* silencing has been shown to augment neuronal vulnerability to cytotoxic events in vitro [27, 35, 179], only a limited number of studies has thus far been published that used a Ngb^{-/-} mouse strain. Most recently, a Ngb^{-/-} mouse was generated, using the knockout-first allele *Ngbtm1a(EUCOMM)Wtsi*, to study a possible role for Ngb in auditory functioning [180]. Ngb depletion resulted in minimal defects in hearing ability and had no impact on noise trauma outcomes. Conversely, auditory brainstem peak-to-peak amplitudes were reduced in Ngb^{-/-} mice 4 weeks after noise trauma. The latter may be grounded in a continuing loss of central neurons, which leads to fewer neurons in the inferior colliculus to transmit signals [180]. Ngb^{-/-} mice have also been used to elucidate the light-induced retinal gene expression response in the mouse retina [88]. Ngb deficiency only caused a small effect on the light-induced retinal gene expression response. However, some other systemic differences were observed with regard to the wild-type condition, e.g. different expression levels of *Akap6*, *Entpd4*, and *Atp8a2* [88]. The first study investigated the transcriptional response to hypoxia in whole Ngb^{-/-} mouse brains [49]. Neuronal viability in these Ngb^{-/-} mice was not altered as compared to wild-type controls, though changes were observed in transcription patterns of the glycolytic pathway as well as increases in HIF1 and c-FOS expression [49]. The latter could be indicative of cells being depleted of Ngb to be more susceptible to hypoxia-induced transcription [49]. However, some genetic buffering might be expected as well, knowing it was already seen in myoglobin knockout mice. Only finding

the correct trigger to induce myoglobin's physiological response and studying its regulatory networks in more detail revealed myoglobin's vital functions [181]. Hence, studying Ngb-linked signaling pathways, using *Ngb* knockout models, may also shed light on cytotoxic pathways in which advantageous participation of Ngb can be expected.

In conclusion, (non)neuronal tissue benefits from an increase in Ngb cellular levels upon cytotoxic events, which contributes to the preservation of tissue integrity. Through an increased attention for Ngb's neuroprotective traits, our understanding has grown on the underlying mechanisms, though most have been intrinsic to Ngb itself. With current research still broadening on the topic of Ngb, we have a good eye on the expansion of our knowledge on Ngb's physiological functions and modes of action.

Acknowledgements Z.P.V.A holds a PhD fellowship from the University of Antwerp (2014BAPDOCPROEX153). E.L is supported by the Research Foundation-Flanders (FWO).

Compliance with Ethical Standards

Conflict of Interest The authors declare that they have no conflict of interest.

References

- Ming GL, Song H (2011) Adult neurogenesis in the mammalian brain: significant answers and significant questions. *Neuron* 70(4):687–702. <https://doi.org/10.1016/j.neuron.2011.05.001>
- Semenza GL (1999) Regulation of mammalian O₂ homeostasis by hypoxia-inducible factor 1. *Annu Rev Cell Dev Biol* 15:551–578. <https://doi.org/10.1146/annurev.cellbio.15.1.551>
- Burmester T, Hankeln T (2014) Function and evolution of vertebrate globins. *Acta Physiol (Oxford)* 211(3):501–514. <https://doi.org/10.1111/apha.12312>
- Burmester T, Weich B, Reinhardt S, Hankeln T (2000) A vertebrate globin expressed in the brain. *Nature* 407(6803):520–523. <https://doi.org/10.1038/35035093>
- Reuss S, Saaler-Reinhardt S, Weich B, Wystub S, Reuss MH, Burmester T, Hankeln T (2002) Expression analysis of neuroglobin mRNA in rodent tissues. *Neuroscience* 115(3):645–656
- Fabrizius A, Andre D, Laufs T, Bicker A, Reuss S, Burmester T, Hankeln T (2016) Critical re-evaluation of neuroglobin expression reveals conserved patterns among mammals. *Neuroscience*. <https://doi.org/10.1016/j.neuroscience.2016.07.042>
- Abbruzzetti S, Faggiano S, Bruno S, Spyraakis F, Mozzarelli A, Dewilde S, Moens L, Viappiani C (2009) Ligand migration through the internal hydrophobic cavities in human neuroglobin. *Proc Natl Acad Sci U S A* 106(45):18984–18989. <https://doi.org/10.1073/pnas.0905433106>
- Fago A, Hundahl C, Dewilde S, Gilany K, Moens L, Weber RE (2004) Allosteric regulation and temperature dependence of oxygen binding in human neuroglobin and cytoglobin. Molecular mechanisms and physiological significance. *J Biol Chem* 279(43):44417–44426. <https://doi.org/10.1074/jbc.M407126200>
- Wystub S, Ebner B, Fuchs C, Weich B, Burmester T, Hankeln T (2004) Interspecies comparison of neuroglobin, cytoglobin and myoglobin: Sequence evolution and candidate regulatory elements. *Cytogenet Genome Res* 105(1):65–78. <https://doi.org/10.1159/000078011>
- Hankeln T, Ebner B, Fuchs C, Gerlach F, Haberkamp M, Laufs TL, Roesner A, Schmidt M et al (2005) Neuroglobin and cytoglobin in search of their role in the vertebrate globin family. *J Inorg Biochem* 99(1):110–119. <https://doi.org/10.1016/j.jinorgbio.2004.11.009>
- Fordel E, Thijs L, Moens L, Dewilde S (2007) Neuroglobin and cytoglobin expression in mice. Evidence for a correlation with reactive oxygen species scavenging. *FEBS J* 274(5):1312–1317. <https://doi.org/10.1111/j.1742-4658.2007.05679.x>
- Pesce A, De Sanctis D, Nardini M, Dewilde S, Moens L, Hankeln T, Burmester T, Ascenzi P et al (2004) Reversible hexa- to penta-coordination of the heme Fe atom modulates ligand binding properties of neuroglobin and cytoglobin. *IUBMB Life* 56(11–12):657–664. <https://doi.org/10.1080/15216540500078830>
- Dewilde S, Kiger L, Burmester T, Hankeln T, Baudin-Creuzza V, Aerts T, Marden MC, Caubergs R et al (2001) Biochemical characterization and ligand binding properties of neuroglobin, a novel member of the globin family. *J Biol Chem* 276(42):38949–38955. <https://doi.org/10.1074/jbc.M106438200>
- Herold S, Fago A, Weber RE, Dewilde S, Moens L (2004) Reactivity studies of the Fe(III) and Fe(II)NO forms of human neuroglobin reveal a potential role against oxidative stress. *J Biol Chem* 279(22):22841–22847. <https://doi.org/10.1074/jbc.M313732200>
- Petersen MG, Dewilde S, Fago A (2008) Reactions of ferrous neuroglobin and cytoglobin with nitrite under anaerobic conditions. *J Inorg Biochem* 102(9):1777–1782. <https://doi.org/10.1016/j.jinorgbio.2008.05.008>
- Yamashita T, Hafsi L, Masuda E, Tsujino H, Uno T (2014) Ferric human neuroglobin scavenges superoxide to form oxy adduct. *Chem Pharm Bull (Tokyo)* 62(6):613–615
- Fago A, Mathews AJ, Moens L, Dewilde S, Brittain T (2006) The reaction of neuroglobin with potential redox protein partners cytochrome b5 and cytochrome c. *FEBS Lett* 580(20):4884–4888. <https://doi.org/10.1016/j.febslet.2006.08.003>
- Picotti P, Dewilde S, Fago A, Hundahl C, De Filippis V, Moens L, Fontana A (2009) Unusual stability of human neuroglobin at low pH—molecular mechanisms and biological significance. *FEBS J* 276(23):7027–7039. <https://doi.org/10.1111/j.1742-4658.2009.07416.x>
- Khan AA, Mao XO, Banwait S, Jin K, Greenberg DA (2007) Neuroglobin attenuates beta-amyloid neurotoxicity in vitro and transgenic Alzheimer phenotype in vivo. *Proc Natl Acad Sci U S A* 104(48):19114–19119. <https://doi.org/10.1073/pnas.0706167104>
- Li RC, Pouranfar F, Lee SK, Morris MW, Wang Y, Gozal D (2008) Neuroglobin protects PC12 cells against beta-amyloid-induced cell injury. *Neurobiol Aging* 29(12):1815–1822. <https://doi.org/10.1016/j.neurobiolaging.2007.05.001>
- Li Y, Dai YB, Sun JY, Xiang Y, Yang J, Dai SY, Zhang X (2015) Neuroglobin attenuates Beta amyloid-induced apoptosis through inhibiting caspases activity by activating PI3K/Akt signaling pathway. *J Mol Neurosci*. <https://doi.org/10.1007/s12031-015-0645-z>
- Chen LM, Xiong YS, Kong FL, Qu M, Wang Q, Chen XQ, Wang JZ, Zhu LQ (2012) Neuroglobin attenuates Alzheimer-like tau hyperphosphorylation by activating Akt signaling. *J Neurochem* 120(1):157–164. <https://doi.org/10.1111/j.1471-4159.2011.07275.x>
- Fordel E, Thijs L, Martinet W, Schrijvers D, Moens L, Dewilde S (2007) Anoxia or oxygen and glucose deprivation in SH-SY5Y cells: a step closer to the unraveling of neuroglobin and cytoglobin functions. *Gene* 398(1–2):114–122. <https://doi.org/10.1016/j.gene.2007.03.022>

24. Emara M, Salloum N, Allalunis-Turner J (2009) Expression and hypoxic up-regulation of neuroglobin in human glioblastoma cells. *Mol Oncol* 3(1):45–53. <https://doi.org/10.1016/j.molonc.2008.11.002>
25. Liu J, Yu Z, Guo S, Lee SR, Xing C, Zhang C, Gao Y, Nicholls DG et al (2009) Effects of neuroglobin overexpression on mitochondrial function and oxidative stress following hypoxia/reoxygenation in cultured neurons. *J Neurosci Res* 87(1):164–170. <https://doi.org/10.1002/jnr.21826>
26. Nayak G, Prentice HM, Milton SL (2009) Role of neuroglobin in regulating reactive oxygen species in the brain of the anoxia-tolerant turtle *Trachemys scripta*. *J Neurochem* 110(2):603–612. <https://doi.org/10.1111/j.1471-4159.2009.06157.x>
27. Lechaue C, Augustin S, Cwerman-Thibault H, Bouaita A, Forster V, Celier C, Rustin P, Marden MC et al (2012) Neuroglobin involvement in respiratory chain function and retinal ganglion cell integrity. *Biochim Biophys Acta* 1823(12):2261–2273. <https://doi.org/10.1016/j.bbamer.2012.09.009>
28. Rayner BS, Duong TT, Myers SJ, Witting PK (2006) Protective effect of a synthetic anti-oxidant on neuronal cell apoptosis resulting from experimental hypoxia re-oxygenation injury. *J Neurochem* 97(1):211–221. <https://doi.org/10.1111/j.1471-4159.2006.03726.x>
29. Duong TT, Antao S, Ellis NA, Myers SJ, Witting PK (2008) Supplementation with a synthetic polyphenol limits oxidative stress and enhances neuronal cell viability in response to hypoxia-re-oxygenation injury. *Brain Res* 1219:8–18. <https://doi.org/10.1016/j.brainres.2008.04.044>
30. Duong TT, Witting PK, Antao ST, Parry SN, Kennerson M, Lai B, Vogt S, Lay PA et al (2009) Multiple protective activities of neuroglobin in cultured neuronal cells exposed to hypoxia re-oxygenation injury. *J Neurochem* 108(5):1143–1154. <https://doi.org/10.1111/j.1471-4159.2008.05846.x>
31. De Marinis E, Acaz-Fonseca E, Arevalo MA, Ascenzi P, Fiochetti M, Marino M, Garcia-Segura LM (2013) 17beta-Estradiol anti-inflammatory effects in primary astrocytes require oestrogen receptor beta-mediated neuroglobin up-regulation. *J Neuroendocrinol* 25(3):260–270. <https://doi.org/10.1111/jne.12007>
32. Kleinknecht A, Popova B, Lazaro DF, Pinho R, Valerius O, Outeiro TF, Braus GH (2016) C-terminal tyrosine residue modifications modulate the protective phosphorylation of serine 129 of alpha-synuclein in a yeast model of Parkinson's disease. *PLoS Genet* 12(6):e1006098. <https://doi.org/10.1371/journal.pgen.1006098>
33. Yu Z, Liu J, Guo S, Xing C, Fan X, Ning M, Yuan JC, Lo EH, Wang X (2009) Neuroglobin-overexpression alters hypoxic response gene expression in primary neuron culture following oxygen glucose deprivation. *Neuroscience* 162 (2):396–403. doi: <https://doi.org/10.1016/j.neuroscience.2009.04.055>
34. Yu Z, Xu J, Liu N, Wang Y, Li X, Pallast S, van Leyen K, Wang X (2012) Mitochondrial distribution of neuroglobin and its response to oxygen-glucose deprivation in primary-cultured mouse cortical neurons. *Neuroscience* 218:235–242. <https://doi.org/10.1016/j.neuroscience.2012.05.054>
35. Yu Z, Liu N, Li Y, Xu J, Wang X (2013) Neuroglobin overexpression inhibits oxygen-glucose deprivation-induced mitochondrial permeability transition pore opening in primary cultured mouse cortical neurons. *Neurobiol Dis* 56:95–103. <https://doi.org/10.1016/j.nbd.2013.04.015>
36. Peroni D, Negro A, Bahr M, Dietz GP (2007) Intracellular delivery of Neuroglobin using HIV-1 TAT protein transduction domain fails to protect against oxygen and glucose deprivation. *Neurosci Lett* 421(2):110–114. <https://doi.org/10.1016/j.neulet.2007.05.046>
37. Fordel E, Thijs L, Martinet W, Lenjou M, Laufs T, Van Bockstaele D, Moens L, Dewilde S (2006) Neuroglobin and cytoglobin over-expression protects human SH-SY5Y neuroblastoma cells against oxidative stress-induced cell death. *Neurosci Lett* 410(2):146–151. <https://doi.org/10.1016/j.neulet.2006.09.027>
38. Zara S, De Colli M, Rapino M, Pacella S, Nasuti C, Sozio P, Di Stefano A, Cataldi A (2013) Ibuprofen and lipoic acid conjugate neuroprotective activity is mediated by Ngb/Akt intracellular signaling pathway in Alzheimer's disease rat model. *Gerontology* 59(3):250–260. <https://doi.org/10.1159/000346445>
39. Szymanski M, Wang R, Fallin MD, Bassett SS, Avramopoulos D (2010) Neuroglobin and Alzheimer's dementia: genetic association and gene expression changes. *Neurobiol Aging* 31(11):1835–1842. <https://doi.org/10.1016/j.neurobiolaging.2008.10.003>
40. Ferrer I, Gomez A, Carmona M, Huesa G, Porta S, Riera-Codina M, Biagioli M, Gustincich S et al (2011) Neuronal hemoglobin is reduced in Alzheimer's disease, argyrophilic grain disease, Parkinson's disease, and dementia with Lewy bodies. *J Alzheimers Dis* 23(3):537–550. <https://doi.org/10.3233/JAD-2010-101485>
41. Lee HM, Greeley GH Jr, Englander EW (2011) Transgenic over-expression of neuroglobin attenuates formation of smoke-inhalation-induced oxidative DNA damage, in vivo, in the mouse brain. *Free Radic Biol Med* 51(12):2281–2287. <https://doi.org/10.1016/j.freeradbiomed.2011.09.026>
42. Gorgun FM, Zhuo M, Singh S, Englander EW (2014) Neuroglobin mitigates mitochondrial impairments induced by acute inhalation of combustion smoke in the mouse brain. *Inhal Toxicol* 26(6):361–369. <https://doi.org/10.3109/08958378.2014.902147>
43. Tae B, Oliveira KC, Conceicao RR, Valenti VE, de Souza JS, Laureano-Melo R, Sato MA, Maciel RM, Giannocco G (2016) Evaluation of globins expression in brain, heart, and lung in rats exposed to side stream cigarette smoke. *Environ Toxicol* doi: <https://doi.org/10.1002/tox.22321>
44. Beltran-Parral L, Acuna D, Ngan AM, Kim E, Ngan A, Kawakami K, Edmond J, Lopez IA (2010) Neuroglobin, cytoglobin, and transcriptional profiling of hypoxia-related genes in the rat cerebellum after prenatal chronic very mild carbon monoxide exposure (25 ppm). *Brain Res* 1330:61–71. <https://doi.org/10.1016/j.brainres.2010.03.005>
45. Cwerman-Thibault H, Lechaue C, Augustin S, Roussel D, Reboussin E, Mohammad A, Degardin-Chicaud J, Simonutti M et al (2017) Neuroglobin can prevent or reverse glaucomatous progression in DBA/2J mice. *Mol Ther Methods Clin Dev* 5: 200–220. <https://doi.org/10.1016/j.omtm.2017.04.008>
46. Sugitani K, Koriyama Y, Sera M, Arai K, Ogai K, Wakasugi K (2017) A novel function of neuroglobin for neuroregeneration in mice after optic nerve injury. *Biochem Biophys Res Commun*. <https://doi.org/10.1016/j.bbrc.2017.09.127>
47. Cardinale A, Fusco FR, Paldino E, Giampa C, Marino M, Nuzzo MT, D'Angelo V, Laurenti D et al (2017) Localization of neuroglobin in the brain of R6/2 mouse model of Huntington's disease. *Neurol Sci*. <https://doi.org/10.1007/s10072-017-3168-2>
48. Nuzzo MT, Fiochetti M, Totta P, Melone MAB, Cardinale A, Fusco FR, Gustincich S, Persichetti F et al (2017) Huntingtin polyQ mutation impairs the 17beta-estradiol/neuroglobin pathway devoted to neuron survival. *Mol Neurobiol* 54(8):6634–6646. <https://doi.org/10.1007/s12035-016-0337-x>
49. Hundahl CA, Luuk H, Ilmjarv S, Falktoft B, Raida Z, Vikesaa J, Friis-Hansen L, Hay-Schmidt A (2011) Neuroglobin-deficiency exacerbates Hif1A and c-FOS response, but does not affect neuronal survival during severe hypoxia in vivo. *PLoS One* 6(12): e28160. <https://doi.org/10.1371/journal.pone.0028160>

50. Hundahl C, Stoltenberg M, Fago A, Weber RE, Dewilde S, Fordel E, Danscher G (2005) Effects of short-term hypoxia on neuroglobin levels and localization in mouse brain tissues. *Neuropathol Appl Neurobiol* 31(6):610–617. <https://doi.org/10.1111/j.1365-2990.2005.00657.x>
51. Avivi A, Gerlach F, Joel A, Reuss S, Burmester T, Nevo E, Hankeln T (2010) Neuroglobin, cytoglobin, and myoglobin contribute to hypoxia adaptation of the subterranean mole rat *Spalax*. *Proc Natl Acad Sci U S A* 107(50):21570–21575. <https://doi.org/10.1073/pnas.1015379107>
52. Fordel E, Geuens E, Dewilde S, De Coen W, Moens L (2004) Hypoxia/ischemia and the regulation of neuroglobin and cytoglobin expression. *IUBMB Life* 56(11–12):681–687. <https://doi.org/10.1080/15216540500037406>
53. Hummler N, Schneider C, Giessl A, Bauer R, Walkinshaw G, Gassmann M, Rascher W, Trollmann R (2012) Acute hypoxia modifies regulation of neuroglobin in the neonatal mouse brain. *Exp Neurol* 236(1):112–121. <https://doi.org/10.1016/j.expneurol.2012.04.006>
54. Mammen PP, Shelton JM, Goetsch SC, Williams SC, Richardson JA, Garry MG, Garry DJ (2002) Neuroglobin, a novel member of the globin family, is expressed in focal regions of the brain. *J Histochem Cytochem* 50(12):1591–1598
55. Li RC, Lee SK, Pouranfar F, Brittan KR, Clair HB, Row BW, Wang Y, Gozal D (2006) Hypoxia differentially regulates the expression of neuroglobin and cytoglobin in rat brain. *Brain Res* 1096(1):173–179. <https://doi.org/10.1016/j.brainres.2006.04.063>
56. Fernando MS, Simpson JE, Matthews F, Brayne C, Lewis CE, Barber R, Kalaria RN, Forster G et al (2006) White matter lesions in an unselected cohort of the elderly: molecular pathology suggests origin from chronic hypoperfusion injury. *Stroke* 37(6):1391–1398. <https://doi.org/10.1161/01.STR.0000221308.94473.14>
57. Li RC, Guo SZ, Lee SK, Gozal D (2010) Neuroglobin protects neurons against oxidative stress in global ischemia. *J Cereb Blood Flow Metab* 30(11):1874–1882. <https://doi.org/10.1038/jcbfm.2010.90>
58. Khan AA, Wang Y, Sun Y, Mao XO, Xie L, Miles E, Graboski J, Chen S et al (2006) Neuroglobin-overexpressing transgenic mice are resistant to cerebral and myocardial ischemia. *Proc Natl Acad Sci U S A* 103(47):17944–17948. <https://doi.org/10.1073/pnas.0607497103>
59. Sun Y, Jin K, Mao XO, Zhu Y, Greenberg DA (2001) Neuroglobin is up-regulated by and protects neurons from hypoxic-ischemic injury. *Proc Natl Acad Sci U S A* 98(26):15306–15311. <https://doi.org/10.1073/pnas.251466698>
60. Sun Y, Jin K, Peel A, Mao XO, Xie L, Greenberg DA (2003) Neuroglobin protects the brain from experimental stroke in vivo. *Proc Natl Acad Sci U S A* 100(6):3497–3500. <https://doi.org/10.1073/pnas.0637726100>
61. Cai B, Lin Y, Xue XH, Fang L, Wang N, Wu ZY (2011) TAT-mediated delivery of neuroglobin protects against focal cerebral ischemia in mice. *Exp Neurol* 227(1):224–231. <https://doi.org/10.1016/j.expneurol.2010.11.009>
62. Hundahl C, Kelsen J, Kjaer K, Ronn LC, Weber RE, Geuens E, Hay-Schmidt A, Nyengaard JR (2006) Does neuroglobin protect neurons from ischemic insult? A quantitative investigation of neuroglobin expression following transient MCAo in spontaneously hypertensive rats. *Brain Res* 1085(1):19–27. <https://doi.org/10.1016/j.brainres.2006.02.040>
63. Ord EN, Shirley R, McClure JD, McCabe C, Kremer EJ, Macrae IM, Work LM (2013) Combined antiapoptotic and antioxidant approach to acute neuroprotection for stroke in hypertensive rats. *J Cereb Blood Flow Metab* 33(8):1215–1224. <https://doi.org/10.1038/jcbfm.2013.70>
64. Schmidt-Kastner R, Haberkamp M, Schmitz C, Hankeln T, Burmester T (2006) Neuroglobin mRNA expression after transient global brain ischemia and prolonged hypoxia in cell culture. *Brain Res* 1103(1):173–180. <https://doi.org/10.1016/j.brainres.2006.05.047>
65. Schubert S, Gerlach F, Stoltenberg-Didinger G, Burmester T, Hankeln T, Boettcher W, Wehsack A, Hubler M et al (2010) Cerebral expression of neuroglobin and cytoglobin after deep hypothermic circulatory arrest in neonatal piglets. *Brain Res* 1356:1–10. <https://doi.org/10.1016/j.brainres.2010.08.005>
66. Wang R, Halper-Stromberg E, Szymanski-Pierce M, Bassett SS, Avramopoulos D (2014) Genetic determinants of neuroglobin transcription. *Neurogenetics* 15(1):65–75. <https://doi.org/10.1007/s10048-013-0388-3>
67. DellaValle B, Hempel C, Kurtzhals JA, Penkowa M (2010) In vivo expression of neuroglobin in reactive astrocytes during neuropathology in murine models of traumatic brain injury, cerebral malaria, and autoimmune encephalitis. *Glia* 58(10):1220–1227. <https://doi.org/10.1002/glia.21002>
68. Li WD, Sun Q, Zhang XS, Wang CX, Li S, Li W, Hang CH (2014) Expression and cell distribution of neuroglobin in the brain tissue after experimental subarachnoid hemorrhage in rats: a pilot study. *Cell Mol Neurobiol* 34(2):247–255. <https://doi.org/10.1007/s10571-013-0008-7>
69. Di Pietro V, Lazzarino G, Amorini AM, Tavazzi B, D'Urso S, Longo S, Vagnozzi R, Signoretti S et al (2014) Neuroglobin expression and oxidant/antioxidant balance after graded traumatic brain injury in the rat. *Free Radic Biol Med* 69:258–264. <https://doi.org/10.1016/j.freeradbiomed.2014.01.032>
70. Purushothuman S, Stone J (2015) The reaction of cerebral cortex to a nearby lesion: Damage, survival, self-protection. *Brain Res* 1601:52–63. <https://doi.org/10.1016/j.brainres.2015.01.003>
71. Zhao S, Yu Z, Zhao G, Xing C, Hayakawa K, Whalen MJ, Lok JM, Lo EH et al (2012) Neuroglobin-overexpression reduces traumatic brain lesion size in mice. *BMC Neurosci* 13:67. <https://doi.org/10.1186/1471-2202-13-67>
72. Taylor JM, Kelley B, Gregory EJ, Berman NE (2014) Neuroglobin overexpression improves sensorimotor outcomes in a mouse model of traumatic brain injury. *Neurosci Lett* 577:125–129. <https://doi.org/10.1016/j.neulet.2014.03.012>
73. Chuang PY, Conley YP, Poloyac SM, Okonkwo DO, Ren D, Sherwood PR, Hravnak M, Alexander SA (2010) Neuroglobin genetic polymorphisms and their relationship to functional outcomes after traumatic brain injury. *J Neurotrauma* 27(6):999–1006. <https://doi.org/10.1089/neu.2009.1129>
74. Jin K, Mao X, Xie L, Greenberg DA (2011) Neuroglobin expression in human arteriovenous malformation and intracerebral hemorrhage. *Acta Neurochir Suppl* 111:315–319. https://doi.org/10.1007/978-3-7091-0693-8_52
75. Haines B, Demaria M, Mao X, Xie L, Campisi J, Jin K, Greenberg DA (2012) Hypoxia-inducible factor-1 and neuroglobin expression. *Neurosci Lett* 514(2):137–140. <https://doi.org/10.1016/j.neulet.2012.01.080>
76. Zhang W, Tian Z, Sha S, Cheng LY, Philipsen S, Tan-Un KC (2011) Functional and sequence analysis of human neuroglobin gene promoter region. *Biochim Biophys Acta* 1809(4–6):236–244. <https://doi.org/10.1016/j.bbagg.2011.02.003>
77. Woo SK, Kwon MS, Geng Z, Chen Z, Ivanov A, Bhatta S, Gerzanich V, Simard JM (2012) Sequential activation of hypoxia-inducible factor 1 and specificity protein 1 is required for hypoxia-induced transcriptional stimulation of Abcc8. *J Cereb Blood Flow Metab* 32(3):525–536. <https://doi.org/10.1038/jcbfm.2011.159>
78. Moeller LC, Broecker-Preuss M (2011) Transcriptional regulation by nonclassical action of thyroid hormone. *Thyroid Res* 4(Suppl 1):S6. <https://doi.org/10.1186/1756-6614-4-S1-S6>

79. Oliveira KC, da Conceicao RR, Piedade GC, de Souza JS, Sato MA, de Barros Maciel RM, Giannocco G (2015) Thyroid hormone modulates neuroglobin and cytoglobin in rat brain. *Metab Brain Dis*. <https://doi.org/10.1007/s11011-015-9718-5>
80. Ma Y, Freitag P, Zhou J, Brune B, Frede S, Fandrey J (2004) Thyroid hormone induces erythropoietin gene expression through augmented accumulation of hypoxia-inducible factor-1. *Am J Phys Regul Integr Comp Phys* 287(3):R600–R607. <https://doi.org/10.1152/ajpregu.00115.2004>
81. Griffin RJ, Moloney A, Kelliher M, Johnston JA, Ravid R, Dockery P, O'Connor R, O'Neill C (2005) Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology. *J Neurochem* 93(1):105–117. <https://doi.org/10.1111/j.1471-4159.2004.02949.x>
82. Sun F, Mao X, Xie L, Greenberg DA, Jin K (2013) Neuroglobin protein is upregulated in Alzheimer's disease. *J Alzheimers Dis* 36(4):659–663. <https://doi.org/10.3233/JAD-130323>
83. Bruning U, Cerone L, Neufeld Z, Fitzpatrick SF, Cheong A, Scholz CC, Simpson DA, Leonard MO et al (2011) MicroRNA-155 promotes resolution of hypoxia-inducible factor 1alpha activity during prolonged hypoxia. *Mol Cell Biol* 31(19):4087–4096. <https://doi.org/10.1128/MCB.01276-10>
84. Van Acker ZP, Luyckx E, Van Leuven W, Geuens E, De Deyn PP, Dam DV, Dewilde S (2017) Impaired hypoxic tolerance in APP23 mice: a dysregulation of neuroprotective globin levels. *FEBS Lett*. <https://doi.org/10.1002/1873-3468.12651>
85. Perluigi M, Di Domenico F, Butterfield DA (2015) mTOR signaling in aging and neurodegeneration: at the crossroad between metabolism dysfunction and impairment of autophagy. *Neurobiol Dis*. <https://doi.org/10.1016/j.nbd.2015.03.014>
86. Sun Y, Jin K, Mao XO, Xie L, Peel A, Childs JT, Logvinova A, Wang X et al (2005) Effect of aging on neuroglobin expression in rodent brain. *Neurobiol Aging* 26(2):275–278. <https://doi.org/10.1016/j.neurobiolaging.2004.03.006>
87. Yu Z, Liu N, Wang Y, Li X, Wang X (2012) Identification of neuroglobin-interacting proteins using yeast two-hybrid screening. *Neuroscience* 200:99–105. <https://doi.org/10.1016/j.neuroscience.2011.10.046>
88. Ilmjarv S, Reimets R, Hundahl CA, Luuk H (2014) Effect of light on global gene expression in the neuroglobin-deficient mouse retina. *Biomed Rep* 2(6):780–786. <https://doi.org/10.3892/br.2014.364>
89. Lu T, Aron L, Zullo J, Pan Y, Kim H, Chen Y, Yang TH, Kim HM et al (2014) REST and stress resistance in ageing and Alzheimer's disease. *Nature* 507(7493):448–454. <https://doi.org/10.1038/nature13163>
90. Chen X, Liu Y, Zhang L, Zhu P, Zhu H, Yang Y, Guan P (2015) Long-term neuroglobin expression of human astrocytes following brain trauma. *Neurosci Lett* 606:194–199. <https://doi.org/10.1016/j.neulet.2015.09.002>
91. Guglielmotto M, Reineri S, Iannello A, Ferrero G, Vanzan L, Miano V, Ricci L, Tamagno E et al (2016) E2 regulates epigenetic signature on neuroglobin enhancer-promoter in neuronal cells. *Front Cell Neurosci* 10:147. <https://doi.org/10.3389/fncel.2016.00147>
92. De Marinis E, Ascenzi P, Pellegrini M, Galluzzo P, Bulzomi P, Arevalo MA, Garcia-Segura LM, Marino M (2010) 17beta-estradiol—a new modulator of neuroglobin levels in neurons: role in neuroprotection against H(2)O(2)-induced toxicity. *Neurosignals* 18(4):223–235. <https://doi.org/10.1159/000323906>
93. Hundahl CA, Kelsen J, Hay-Schmidt A (2013) Neuroglobin and cytoglobin expression in the human brain. *Brain Struct Funct* 218(2):603–609. <https://doi.org/10.1007/s00429-012-0480-8>
94. Brittain T (2012) The anti-apoptotic role of neuroglobin. *Cells* 1(4):1133–1155. <https://doi.org/10.3390/cells1041133>
95. Liu N, Yu Z, Li Y, Yuan J, Zhang J, Xiang S, Wang X (2013) Transcriptional regulation of mouse neuroglobin gene by cyclic AMP responsive element binding protein (CREB) in N2a cells. *Neurosci Lett* 534:333–337. <https://doi.org/10.1016/j.neulet.2012.11.025>
96. Sakamoto K, Karelina K, Obrietan K (2011) CREB: a multifaceted regulator of neuronal plasticity and protection. *J Neurochem* 116(1):1–9. <https://doi.org/10.1111/j.1471-4159.2010.07080.x>
97. Zhu Y, Sun Y, Jin K, Greenberg DA (2002) Hemin induces neuroglobin expression in neural cells. *Blood* 100(7):2494–2498. <https://doi.org/10.1182/blood-2002-01-0280>
98. Jin K, Mao XO, Xie L, John V, Greenberg DA (2011) Pharmacological induction of neuroglobin expression. *Pharmacology* 87(1–2):81–84. <https://doi.org/10.1159/000322998>
99. Safe S (2001) Transcriptional activation of genes by 17 beta-estradiol through estrogen receptor-Sp1 interactions. *Vitam Horm* 62:231–252
100. Pinto-Almazan R, Segura-Urbe JJ, Farfan-Garcia ED, Guerra-Araiza C (2017) Effects of tibolone on the central nervous system: clinical and experimental approaches. *Biomed Res Int* 2017:8630764. <https://doi.org/10.1155/2017/8630764>
101. Avila-Rodriguez M, Garcia-Segura LM, Hidalgo-Lanussa O, Baez E, Gonzalez J, Barreto GE (2016) Tibolone protects astrocytic cells from glucose deprivation through a mechanism involving estrogen receptor beta and the upregulation of neuroglobin expression. *Mol Cell Endocrinol*. <https://doi.org/10.1016/j.mce.2016.05.024>
102. Liu N, Yu Z, Gao X, Song YS, Yuan J, Xun Y, Wang T, Yan F et al (2016) Establishment of cell-based neuroglobin promoter reporter assay for neuroprotective compounds screening. *CNS Neurol Disord Drug Targets*
103. Ye Q, Sun Y, Wu Y, Gao Y, Li Z, Li W, Zhang C (2015) Pichia pastoris production of tat-NGB and its neuroprotection on rat pheochromocytoma cells. *Mol Biotechnol*. <https://doi.org/10.1007/s12033-015-9898-6>
104. Azarov I, Wang L, Rose JJ, Xu Q, Huang XN, Belanger A, Wang Y, Guo L et al (2016) Five-coordinate H64Q neuroglobin as a ligand-trap antidote for carbon monoxide poisoning. *Sci Transl Med* 8(368):368ra173. <https://doi.org/10.1126/scitranslmed.aah6571>
105. Pesce A, Dewilde S, Nardini M, Moens L, Ascenzi P, Hankeln T, Burmester T, Bolognesi M (2003) Human brain neuroglobin structure reveals a distinct mode of controlling oxygen affinity. *Structure* 11(9):1087–1095
106. Hamdane D, Kiger L, Dewilde S, Green BN, Pesce A, Uzan J, Burmester T, Hankeln T et al (2003) The redox state of the cell regulates the ligand binding affinity of human neuroglobin and cytoglobin. *J Biol Chem* 278(51):51713–51721. <https://doi.org/10.1074/jbc.M309396200>
107. Hamdane D, Kiger L, Dewilde S, Green BN, Pesce A, Uzan J, Burmester T, Hankeln T et al (2004) Coupling of the heme and an internal disulfide bond in human neuroglobin. *Micron* 35(1–2):59–62. <https://doi.org/10.1016/j.micron.2003.10.019>
108. Van Doorslaer S, Dewilde S, Kiger L, Nistor SV, Goovaerts E, Marden MC, Moens L (2003) Nitric oxide binding properties of neuroglobin. A characterization by EPR and flash photolysis. *J Biol Chem* 278(7):4919–4925. <https://doi.org/10.1074/jbc.M210617200>
109. Jin K, Mao XO, Xie L, Khan AA, Greenberg DA (2008) Neuroglobin protects against nitric oxide toxicity. *Neurosci Lett* 430(2):135–137. <https://doi.org/10.1016/j.neulet.2007.10.031>
110. Van Leuven W, Cuypers B, Desmet F, Giordano D, Verde C, Moens L, Van Doorslaer S, Dewilde S (2013) Is the heme pocket region modulated by disulfide-bridge formation in fish and amphibian neuroglobins as in humans? *Biochim Biophys Acta*

- 1834(9):1757–1763. <https://doi.org/10.1016/j.bbapap.2013.01.042>
111. Vinck E, Van Doorslaer S, Dewilde S, Moens L (2004) Structural change of the heme pocket due to disulfide bridge formation is significantly larger for neuroglobin than for cytoglobin. *J Am Chem Soc* 126(14):4516–4517. <https://doi.org/10.1021/ja0383322>
112. Bentmann A, Schmidt M, Reuss S, Wolfrum U, Hankeln T, Burmester T (2005) Divergent distribution in vascular and avascular mammalian retinae links neuroglobin to cellular respiration. *J Biol Chem* 280(21):20660–20665. <https://doi.org/10.1074/jbc.M501338200>
113. Mitz SA, Reuss S, Folkow LP, Blix AS, Ramirez JM, Hankeln T, Burmester T (2009) When the brain goes diving: glial oxidative metabolism may confer hypoxia tolerance to the seal brain. *Neuroscience* 163(2):552–560. <https://doi.org/10.1016/j.neuroscience.2009.06.058>
114. Brown GC (2001) Regulation of mitochondrial respiration by nitric oxide inhibition of cytochrome c oxidase. *Biochim Biophys Acta* 1504(1):46–57
115. Tiso M, Tejero J, Basu S, Azarov I, Wang X, Simplaceanu V, Frizzell S, Jayaraman T et al (2011) Human neuroglobin functions as a redox-regulated nitrite reductase. *J Biol Chem* 286(20):18277–18289. <https://doi.org/10.1074/jbc.M110.159541>
116. Jayaraman T, Tejero J, Chen BB, Blood AB, Frizzell S, Shapiro C, Tiso M, Hood BL et al (2011) 14-3-3 binding and phosphorylation of neuroglobin during hypoxia modulate six-to-five heme pocket coordination and rate of nitrite reduction to nitric oxide. *J Biol Chem* 286(49):42679–42689. <https://doi.org/10.1074/jbc.M111.271973>
117. Yu Z, Zhang Y, Liu N, Yuan J, Lin L, Zhuge Q, Xiao J, Wang X (2016) Roles of neuroglobin binding to mitochondrial complex III subunit cytochrome c1 in oxygen-glucose deprivation-induced neurotoxicity in primary neurons. *Mol Neurobiol* 53(5):3249–3257. <https://doi.org/10.1007/s12035-015-9273-4>
118. Varjosalo M, Sacco R, Stukalov A, van Drogen A, Planyavsky M, Hauri S, Aebersold R, Bennett KL et al (2013) Interlaboratory reproducibility of large-scale human protein-complex analysis by standardized AP-MS. *Nat Methods* 10(4):307–314. <https://doi.org/10.1038/nmeth.2400>
119. Wakasugi K, Nakano T, Morishima I (2004) Association of human neuroglobin with cystatin C, a cysteine proteinase inhibitor. *Biochemistry* 43(18):5119–5125. <https://doi.org/10.1021/bi0495782>
120. Wakasugi K, Nakano T, Kitatsuji C, Morishima I (2004) Human neuroglobin interacts with flotillin-1, a lipid raft microdomain-associated protein. *Biochem Biophys Res Commun* 318(2):453–460. <https://doi.org/10.1016/j.bbrc.2004.04.045>
121. Khan AA, Mao XO, Banwait S, DerMardirossian CM, Bokoch GM, Jin K, Greenberg DA (2008) Regulation of hypoxic neuronal death signaling by neuroglobin. *FASEB J* 22(6):1737–1747. <https://doi.org/10.1096/fj.07-100784>
122. Wakasugi K, Nakano T, Morishima I (2003) Oxidized human neuroglobin acts as a heterotrimeric Galpha protein guanine nucleotide dissociation inhibitor. *J Biol Chem* 278(38):36505–36512. <https://doi.org/10.1074/jbc.M305519200>
123. Trandafir F, Hoogewijs D, Altieri F, Rivetti di Val Cervo P, Ramser K, Van Doorslaer S, Vanfleteren JR, Moens L et al (2007) Neuroglobin and cytoglobin as potential enzyme or substrate. *Gene* 398(1–2):103–113. <https://doi.org/10.1016/j.gene.2007.02.038>
124. Madesh M, Hajnoczky G (2001) VDAC-dependent permeabilization of the outer mitochondrial membrane by superoxide induces rapid and massive cytochrome c release. *J Cell Biol* 155(6):1003–1015. <https://doi.org/10.1083/jcb.200105057>
125. Vaseva AV, Marchenko ND, Ji K, Tsirka SE, Holzmann S, Moll UM (2012) p53 opens the mitochondrial permeability transition pore to trigger necrosis. *Cell* 149(7):1536–1548. <https://doi.org/10.1016/j.cell.2012.05.014>
126. Fuchs C, Heib V, Kiger L, Haberkamp M, Roesner A, Schmidt M, Hamdane D, Marden MC et al (2004) Zebrafish reveals different and conserved features of vertebrate neuroglobin gene structure, expression pattern, and ligand binding. *J Biol Chem* 279(23):24116–24122. <https://doi.org/10.1074/jbc.M402011200>
127. Paltrinieri L, Di Rocco G, Battistuzzi G, Borsari M, Sola M, Ranieri A, Zanetti-Polzi L, Daidone I et al (2017) Computational evidence support the hypothesis of neuroglobin also acting as an electron transfer species. *J Biol Inorg Chem*. <https://doi.org/10.1007/s00775-017-1455-2>
128. Watanabe S, Takahashi N, Uchida H, Wakasugi K (2012) Human neuroglobin functions as an oxidative stress-responsive sensor for neuroprotection. *J Biol Chem* 287(36):30128–30138. <https://doi.org/10.1074/jbc.M112.373381>
129. Takahashi N, Wakasugi K (2016) Identification of residues crucial for the interaction between human neuroglobin and the alpha-subunit of heterotrimeric Gi protein. *Sci Rep* 6:24948. <https://doi.org/10.1038/srep24948>
130. Li RC, Morris MW, Lee SK, Pouranfar F, Wang Y, Gozal D (2008) Neuroglobin protects PC12 cells against oxidative stress. *Brain Res* 1190:159–166. <https://doi.org/10.1016/j.brainres.2007.11.022>
131. Tian J, Cai T, Yuan Z, Wang H, Liu L, Haas M, Maksimova E, Huang XY et al (2006) Binding of Src to Na⁺/K⁺-ATPase forms a functional signaling complex. *Mol Biol Cell* 17(1):317–326. <https://doi.org/10.1091/mbc.E05-08-0735>
132. Liu A, Brittain T (2015) A futile redox cycle involving neuroglobin observed at physiological temperature. *Int J Mol Sci* 16(8):20082–20094. <https://doi.org/10.3390/ijms160820082>
133. Sowa AW, Guy PA, Sowa S, Hill RD (1999) Nonsymbiotic haemoglobins in plants. *Acta Biochim Pol* 46(2):431–445
134. Brittain T, Skommer J, Henty K, Birch N, Raychaudhuri S (2010) A role for human neuroglobin in apoptosis. *IUBMB Life* 62(12):878–885. <https://doi.org/10.1002/iub.405>
135. Curtin NJ (2012) DNA repair dysregulation from cancer driver to therapeutic target. *Nat Rev Cancer* 12(12):801–817. <https://doi.org/10.1038/nrc3399>
136. Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, Lichter T, Decker WK et al (2015) Immune evasion in cancer: Mechanistic basis and therapeutic strategies. *Semin Cancer Biol* 35(Suppl):S185–S198. <https://doi.org/10.1016/j.semcancer.2015.03.004>
137. Oleksiewicz U, Daskoulidou N, Liloglou T, Tasopoulou K, Bryan J, Gosney JR, Field JK, Xinarianos G (2011) Neuroglobin and myoglobin in non-small cell lung cancer: expression, regulation and prognosis. *Lung Cancer* 74(3):411–418. <https://doi.org/10.1016/j.lungcan.2011.05.001>
138. Emará M, Turner AR, Allalunis-Turner J (2010) Hypoxic regulation of cytoglobin and neuroglobin expression in human normal and tumor tissues. *Cancer Cell Int* 10:33. <https://doi.org/10.1186/1475-2867-10-33>
139. Gorr TA, Wichmann D, Pilarsky C, Theurillat JP, Fabrizius A, Laufs T, Bauer T, Koslowski M et al (2011) Old proteins - new locations: myoglobin, haemoglobin, neuroglobin and cytoglobin in solid tumours and cancer cells. *Acta Physiol (Oxford)* 202(3):563–581. <https://doi.org/10.1111/j.1748-1716.2010.02205.x>
140. Fiocchetti M, Cipolletti M, Leone S, Naldini A, Carraro F, Giordano D, Verde C, Ascenzi P et al (2016) Neuroglobin in breast Cancer cells: effect of hypoxia and oxidative stress on protein level, localization, and anti-apoptotic function. *PLoS One* 11(5):e0154959. <https://doi.org/10.1371/journal.pone.0154959>
141. Guo ZL, Richardson DR, Kalinowski DS, Kovacevic Z, Tan-Un KC, Chan GC (2016) The novel thiosemicarbazone, di-2-

- pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), inhibits neuroblastoma growth in vitro and in vivo via multiple mechanisms. *J Hematol Oncol* 9(1):98. <https://doi.org/10.1186/s13045-016-0330-x>
142. Fiocchetti M, Cipolletti M, Leone S, Ascenzi P, Marino M (2016) Neuroglobin overexpression induced by the 17 β -estradiol-estrogen receptor- α pathway reduces the sensitivity of MCF-7 breast cancer cell to paclitaxel. *IUBMB Life*. <https://doi.org/10.1002/iub.1522>
 143. Chen XQ, Qin LY, Zhang CG, Yang LT, Gao Z, Liu S, Lau LT, Fung YW et al (2005) Presence of neuroglobin in cultured astrocytes. *Glia* 50(2):182–186. <https://doi.org/10.1002/glia.20147>
 144. Laufs TL, Wystub S, Reuss S, Burmester T, Saaler-Reinhardt S, Hankeln T (2004) Neuron-specific expression of neuroglobin in mammals. *Neurosci Lett* 362(2):83–86. <https://doi.org/10.1016/j.neulet.2004.02.072>
 145. Haines B, Mao X, Xie L, Spusta S, Zeng X, Jin K, Greenberg DA (2013) Neuroglobin expression in neurogenesis. *Neurosci Lett* 549:3–6. <https://doi.org/10.1016/j.neulet.2013.04.039>
 146. Toro-Urrego N, Garcia-Segura LM, Echeverria V, Barreto GE (2016) Testosterone protects mitochondrial function and regulates neuroglobin expression in astrocytic cells exposed to glucose deprivation. *Front Aging Neurosci* 8:152. <https://doi.org/10.3389/fnagi.2016.00152>
 147. Schnerer M, Flachsbarth S, Czech-Damal NU, Folkow LP, Siebert U, Burmester T (2012) Neuroglobin of seals and whales: evidence for a divergent role in the diving brain. *Neuroscience* 223:35–44. <https://doi.org/10.1016/j.neuroscience.2012.07.052>
 148. Buffo A, Rolando C, Ceruti S (2010) Astrocytes in the damaged brain: Molecular and cellular insights into their reactive response and healing potential. *Biochem Pharmacol* 79(2):77–89. <https://doi.org/10.1016/j.bcp.2009.09.014>
 149. Cabezas R, Vega-Vela NE, Gonzalez-Sanmiguel J, Gonzalez J, Esquinas P, Echeverria V, Barreto GE (2017) PDGF-BB preserves mitochondrial morphology, attenuates ROS production, and upregulates neuroglobin in an astrocytic model under rotenone insult. *Mol Neurobiol*. <https://doi.org/10.1007/s12035-017-0567-6>
 150. Jin K, Mao Y, Mao X, Xie L, Greenberg DA (2010) Neuroglobin expression in ischemic stroke. *Stroke* 41(3):557–559. <https://doi.org/10.1161/STROKEAHA.109.567149>
 151. Lechaue C, Augustin S, Cwerman-Thibault H, Reboussin E, Roussel D, Lai-Kuen R, Saubamea B, Sahel JA et al (2014) Neuroglobin gene therapy prevents optic atrophy and preserves durably visual function in Harlequin mice. *Mol Ther* 22(6):1096–1109. <https://doi.org/10.1038/mt.2014.44>
 152. Dobolyi A, Vincze C, Pal G, Lovas G (2012) The neuroprotective functions of transforming growth factor beta proteins. *Int J Mol Sci* 13(7):8219–8258. <https://doi.org/10.3390/ijms13078219>
 153. Khundakar A, Morris C, Slade J, Thomas AJ (2011) Examination of glucose transporter-1, transforming growth factor-beta and neuroglobin immunoreactivity in the orbitofrontal cortex in late-life depression. *Psychiatry Clin Neurosci* 65(2):158–164. <https://doi.org/10.1111/j.1440-1819.2010.02176.x>
 154. Lechaue C, Augustin S, Roussel D, Sahel JA, Corral-Debrinski M (2013) Neuroglobin involvement in visual pathways through the optic nerve. *Biochim Biophys Acta* 1834(9):1772–1778. <https://doi.org/10.1016/j.bbapap.2013.04.014>
 155. Baez-Jurado E, Vega GG, Aliev G, Tarasov VV, Esquinas P, Echeverria V, Barreto GE (2017) Blockade of neuroglobin reduces protection of conditioned medium from human mesenchymal stem cells in human astrocyte model (T98G) under a scratch assay. *Mol Neurobiol*. <https://doi.org/10.1007/s12035-017-0481-y>
 156. Luyckx E, Everaert BR, Van der Veken B, Van Leuven W, Timmermans JP, Vrints CJ, De Meyer GRY, Martinet W et al (2017) Cytoprotective effects of transgenic neuroglobin overexpression in an acute and chronic mouse model of ischemic heart disease. *Heart Vessel*. <https://doi.org/10.1007/s00380-017-1065-5>
 157. Cutrupi S, Ferrero G, Reineri S, Cordero F, De Bortoli M (2014) Genomic lens on neuroglobin transcription. *IUBMB Life* 66(1):46–51. <https://doi.org/10.1002/iub.1235>
 158. D'Aprile A, Scrima R, Quarato G, Tataranni T, Falzetti F, Di Ianni M, Gemei M, Del Vecchio L et al (2014) Hematopoietic stem/progenitor cells express myoglobin and neuroglobin: adaptation to hypoxia or prevention from oxidative stress? *Stem Cells* 32(5):1267–1277. <https://doi.org/10.1002/stem.1646>
 159. Tam KT, Chan PK, Zhang W, Law PP, Tian Z, Fung Chan GC, Philipson S, Festenstein R et al (2016) Identification of a novel distal regulatory element of the human Neuroglobin gene by the chromosome conformation capture approach. *Nucleic Acids Res*. <https://doi.org/10.1093/nar/gkw820>
 160. Nefzger CM, Haynes JM, Pouton CW (2011) Directed expression of Gata2, Mash1, and Foxa2 synergize to induce the serotonergic neuron phenotype during in vitro differentiation of embryonic stem cells. *Stem Cells* 29(6):928–939. <https://doi.org/10.1002/stem.640>
 161. Willett RT, Greene LA (2011) Gata2 is required for migration and differentiation of retinorecipient neurons in the superior colliculus. *J Neurosci* 31(12):4444–4455. <https://doi.org/10.1523/JNEUROSCI.4616-10.2011>
 162. Droge J, Pande A, Englander EW, Makalowski W (2012) Comparative genomics of neuroglobin reveals its early origins. *PLoS One* 7(10):e47972. <https://doi.org/10.1371/journal.pone.0047972>
 163. Wilber A, Nienhuis AW, Persons DA (2011) Transcriptional regulation of fetal to adult hemoglobin switching: new therapeutic opportunities. *Blood* 117(15):3945–3953. <https://doi.org/10.1182/blood-2010-11-316893>
 164. Yan Z, Serrano AL, Schiaffino S, Bassel-Duby R, Williams RS (2001) Regulatory elements governing transcription in specialized myofiber subtypes. *J Biol Chem* 276(20):17361–17366. <https://doi.org/10.1074/jbc.M101251200>
 165. Jin K, Wang X, Xie L, Mao XO, Greenberg DA (2010) Transgenic ablation of doublecortin-expressing cells suppresses adult neurogenesis and worsens stroke outcome in mice. *Proc Natl Acad Sci U S A* 107(17):7993–7998. <https://doi.org/10.1073/pnas.1000154107>
 166. Li L, Liu QR, Xiong XX, Liu JM, Lai XJ, Cheng C, Pan F, Chen Y et al (2014) Neuroglobin promotes neurite outgrowth via differential binding to PTEN and Akt. *Mol Neurobiol* 49(1):149–162. <https://doi.org/10.1007/s12035-013-8506-7>
 167. Sugitani K, Koriyama Y, Ogai K, Wakasugi K, Kato S (2016) A possible role of neuroglobin in the retina after optic nerve injury: a comparative study of zebrafish and mouse retina. *Adv Exp Med Biol* 854:671–675. https://doi.org/10.1007/978-3-319-17121-0_89
 168. Liang H, Studach L, Hullinger RL, Xie J, Andrisani OM (2014) Down-regulation of RE-1 silencing transcription factor (REST) in advanced prostate cancer by hypoxia-induced miR-106b–25. *Exp Cell Res* 320(2):188–199. <https://doi.org/10.1016/j.yexcr.2013.09.020>
 169. Roesner A, Hankeln T, Burmester T (2006) Hypoxia induces a complex response of globin expression in zebrafish (*Danio rerio*). *J Exp Biol* 209(Pt 11):2129–2137. <https://doi.org/10.1242/jeb.02243>
 170. Di Giulio C, Zara S, Cataldi A, Porzionato A, Pokorski M, De Caro R (2012) Human carotid body HIF and NGB expression during human development and aging. *Adv Exp Med Biol* 758:265–271. https://doi.org/10.1007/978-94-007-4584-1_36
 171. Verratti V, Di Giulio C, Bianchi G, Cacchio M, Petrucci G, Artese L, Lahiri S, Iturriaga R (2009) Neuroglobin in aging carotid

- bodies. *Adv Exp Med Biol* 648:191–195. https://doi.org/10.1007/978-90-481-2259-2_22
172. Williams TM, Zavanelli M, Miller MA, Goldbeck RA, Morledge M, Casper D, Pabst DA, McLellan W et al (2008) Running, swimming and diving modifies neuroprotecting globins in the mammalian brain. *Proc Biol Sci* 275(1636):751–758. <https://doi.org/10.1098/rspb.2007.1484>
173. Roesner A, Mitz SA, Hankeln T, Burmester T (2008) Globins and hypoxia adaptation in the goldfish, *Carassius auratus*. *FEBS J* 275(14):3633–3643. <https://doi.org/10.1111/j.1742-4658.2008.06508.x>
174. Wawrowski A, Gerlach F, Hankeln T, Burmester T (2011) Changes of globin expression in the Japanese medaka (*Oryzias latipes*) in response to acute and chronic hypoxia. *J Comp Physiol B* 181(2):199–208. <https://doi.org/10.1007/s00360-010-0518-2>
175. Hoffmann FG, Opazo JC, Storz JF (2012) Whole-genome duplications spurred the functional diversification of the globin gene superfamily in vertebrates. *Mol Biol Evol* 29(1):303–312. <https://doi.org/10.1093/molbev/msr207>
176. Lechauve C, Jager M, Laguerre L, Kiger L, Correc G, Leroux C, Vinogradov S, Czjzek M et al (2013) Neuroglobins, pivotal proteins associated with emerging neural systems and precursors of metazoan globin diversity. *J Biol Chem* 288(10):6957–6967. <https://doi.org/10.1074/jbc.M112.407601>
177. Ascenzi P, di Masi A, Leboffe L, Flocchetti M, Nuzzo MT, Brunori M, Marino M (2016) Neuroglobin: from structure to function in health and disease. *Mol Asp Med* 52:1–48. <https://doi.org/10.1016/j.mam.2016.10.004>
178. Van Leuven W, Van Dam D, Moens L, De Deyn PP, Dewilde S (2013) A behavioural study of neuroglobin-overexpressing mice under normoxic and hypoxic conditions. *Biochim Biophys Acta* 1834(9):1764–1771. <https://doi.org/10.1016/j.bbapap.2013.04.015>
179. Ye SQ, Zhou XY, Lai XJ, Zheng L, Chen XQ (2009) Silencing neuroglobin enhances neuronal vulnerability to oxidative injury by down-regulating 14-3-3gamma. *Acta Pharmacol Sin* 30(7):913–918. <https://doi.org/10.1038/aps.2009.70>
180. Nowotny M, Kiefer L, Andre D, Hankeln T, Reuss S (2017) Hearing without neuroglobin. *Neuroscience*. <https://doi.org/10.1016/j.neuroscience.2017.10.010>
181. Totzeck M, Hendgen-Cotta UB, Luedike P, Berenbrink M, Klare JP, Steinhoff HJ, Semmler D, Shiva S et al (2012) Nitrite regulates hypoxic vasodilation via myoglobin-dependent nitric oxide generation. *Circulation* 126(3):325–334. <https://doi.org/10.1161/CIRCULATIONAHA.111.087155>